II 

Calendar No. 667 

118TH CONGRESS 

2D SESSION S. 4667 

[Report No. 118–264] 

To amend title 31, United States Code, to establish the Life Sciences 

Research Security Board, and for other purposes. 

IN THE SENATE OF THE UNITED STATES 

JULY 10, 2024 

Mr. PAUL (for himself and Mr. PETERS) introduced the following bill; which 

was read twice and referred to the Committee on Homeland Security and 

Governmental Affairs 

DECEMBER 5, 2024 

Reported by Mr. PETERS, with an amendment 

[Strike out all after the enacting clause and insert the part printed in italic] 

A BILL 

To amend title 31, United States Code, to establish the 

Life Sciences Research Security Board, and for other 

purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Risky Research Review 

5 Act’’. 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•S 4667 RS

1 SEC. 2. LIFE SCIENCES RESEARCH SECURITY BOARD. 

2 (a) IN GENERAL.—Subtitle V of title 31, United 

3 States Code, is amended by adding at the end the fol4 lowing: 

5 ‘‘CHAPTER 79—LIFE SCIENCES RESEARCH 

6 SECURITY BOARD 

7 ‘‘§ 7901. Definitions 

8 ‘‘In this chapter: 

9 ‘‘(1) AGENCY.—The term ‘agency’ has the 

10 meaning given the term in section 552(f) of title 5. 

11 ‘‘(2) APPROPRIATE CONGRESSIONAL COMMIT12 TEES.—The term ‘appropriate congressional com13 mittees’ means the Committee on Homeland Secu14 rity and Governmental Affairs of the Senate and the 

15 Committee on Oversight and Accountability of the 

16 House of Representatives. 

17 ‘‘(3) BOARD.—The term ‘Board’ means the 

18 Life Sciences Research Security Board established 

19 under section 7902(a). 

20 ‘‘(4) DUAL USE.—The term ‘dual use’, with re21 spect to research, means research that, based on 

22 current understanding as of the date of research, 

23 can be reasonably anticipated to provide knowledge, 

24 information, products, or technologies that could di25 rectly or with only minor modification be misapplied 

26 to pose a significant threat with broad potential conVerDate Sep 11 2014 00:24 Dec 06, 2024 Jkt 059200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6401 E:\BILLS\S4667.RS S4667

ssavage on LAPJG3WLY3PROD with BILLS
3 

•S 4667 RS

1 sequences to public health and safety, agricultural 

2 crops or other plants, animals, materiel, or national 

3 security. 

4 ‘‘(5) EMPLOYEE.— 

5 ‘‘(A) IN GENERAL.—The term ‘em6 ployee’— 

7 ‘‘(i) means an employee of an agency; 

8 and 

9 ‘‘(ii) includes an individual, other than 

10 an employee of an agency, working under 

11 a contract with an agency. 

12 ‘‘(B) RULE OF CONSTRUCTION.—With re13 spect to an individual described in subpara14 graph (A)(ii), solely for the purposes of this 

15 chapter, the agency that has entered into the 

16 contract under which the employee is working 

17 shall be construed to be the agency employing 

18 the employee. 

19 ‘‘(6) FEDERAL FUNDING.—The term ‘Federal 

20 funding’— 

21 ‘‘(A) means amounts awarded by an agen22 cy pursuant to a grant, cooperative agreement, 

23 interagency agreement, contract, or other in24 strument; and 

25 ‘‘(B) includes— 


ssavage on LAPJG3WLY3PROD with BILLS
4 

•S 4667 RS

1 ‘‘(i) an in-kind contribution by an 

2 agency used for life sciences research pur3 poses; and 

4 ‘‘(ii) research conducted by an agency 

5 to which funds were appropriated for con6 ducting research. 

7 ‘‘(7) GAIN OF FUNCTION RESEARCH.—The 

8 term ‘gain of function research’ means research that 

9 has the potential to enhance the transmissibility or 

10 virulence of a potential pandemic pathogen. 

11 ‘‘(8) HIGH-RISK LIFE SCIENCES RESEARCH.— 

12 The term ‘high-risk life sciences research’— 

13 ‘‘(A) means life sciences research that— 

14 ‘‘(i) has a potential dual use nature; 

15 or 

16 ‘‘(ii) could pose a threat to public 

17 health, safety, or national security; and 

18 ‘‘(B) includes— 

19 ‘‘(i) gain of function research; 

20 ‘‘(ii) research involving a potential 

21 pandemic pathogen, including genetic 

22 modification of a potential pandemic 

23 pathogen and the synthetic creation of a 

24 potential pandemic pathogen; and 


ssavage on LAPJG3WLY3PROD with BILLS
5 

•S 4667 RS

1 ‘‘(iii) an activity involving the collec2 tion or surveillance of a potential pandemic 

3 pathogen. 

4 ‘‘(9) LIFE SCIENCES RESEARCH.—The term 

5 ‘life sciences research’ means research in agricul6 tural biotechnology, biogenerics, bioinformatics, bio7 medical engineering, biopharmaceuticals, academic 

8 medical centers, biotechnology, chemical synthesis, 

9 chemistry technology, medical diagnostics, genomics, 

10 medical image analysis, marine biology, medical de11 vices, medical nanotechnology, natural product phar12 maceuticals proteomics, regenerative medicine, RNA 

13 interference, stem cell research, medical and neuro14 logical clinical trials, health robotics, and veterinary 

15 science. 

16 ‘‘(10) POTENTIAL PANDEMIC PATHOGEN.—The 

17 term ‘potential pandemic pathogen’— 

18 ‘‘(A) means a virus, natural or synthetic, 

19 bacteria, fungus, prion, or eukaryotic parasite, 

20 or any strain or variant of a virus, bacterium, 

21 fungus, prion, or eukaryotic parasite— 

22 ‘‘(i) that— 

23 ‘‘(I) is reasonably anticipated to 

24 be moderately or highly transmissible 

25 and likely capable of wide and unconVerDate Sep 11 2014 00:24 Dec 06, 2024 Jkt 059200 PO 00000 Frm 00005 Fmt 6652 Sfmt 6401 E:\BILLS\S4667.RS S4667

ssavage on LAPJG3WLY3PROD with BILLS
6 

•S 4667 RS

1 trollable spread in human populations; 

2 and 

3 ‘‘(II) is described in clause (ii) or 

4 (iii); and 

5 ‘‘(ii) reasonably anticipated to be of 

6 low, moderate, or high virulence and likely 

7 to cause significant morbidity or mortality 

8 in humans; or 

9 ‘‘(iii) reasonably anticipated to pose a 

10 severe threat to public health, the capacity 

11 of public health systems to function, or na12 tional security if allowed to spread within 

13 the general population; and 

14 ‘‘(B) includes— 

15 ‘‘(i) subject to subparagraph (C), in16 fluenza viruses; 

17 ‘‘(ii) sarbecoviruses; 

18 ‘‘(iii) merbecoviruses; 

19 ‘‘(iv) henipaviruses, including Nipah 

20 virus; 

21 ‘‘(v) filoviruses; 

22 ‘‘(vi) arenaviruses; 

23 ‘‘(vii) orthopoxviruses; 

24 ‘‘(viii) Yersinia pestis; 


ssavage on LAPJG3WLY3PROD with BILLS
7 

•S 4667 RS

1 ‘‘(ix) any synthetic construct of such 

2 viruses; and 

3 ‘‘(x) a select agent or toxin, work with 

4 which poses a significant risk of deliberate 

5 misuse; and 

6 ‘‘(C) does not include seasonal influenza 

7 viruses, unless such viruses have been manipu8 lated to include genetic sequences from a poten9 tial pandemic pathogen. 

10 ‘‘(11) SELECT AGENT OR TOXIN.—The term 

11 ‘select agent or toxin’ means an agent or toxin iden12 tified under— 

13 ‘‘(A) section 73.3(b) of title 42, Code of 

14 Federal Regulations, as in effect on the date of 

15 enactment of the Risky Research Review Act; 

16 ‘‘(B) section 331.3(b) of title 7, Code of 

17 Federal Regulations, as in effect on the date of 

18 enactment of the Risky Research Review Act; 

19 or 

20 ‘‘(C) section 121.3(b) of title 9, Code of 

21 Federal Regulations, as in effect on the date of 

22 enactment of the Risky Research Review Act. 

23 ‘‘§ 7902. Establishment and membership 

24 ‘‘(a) ESTABLISHMENT.—There is established as an 

25 independent agency within the Executive Branch a board 


ssavage on LAPJG3WLY3PROD with BILLS
8 

•S 4667 RS

1 to be known as the ‘Life Sciences Research Security 

2 Board’ to review proposed Federal funding for life sciences 

3 research in accordance with section 7906. 

4 ‘‘(b) APPOINTMENT OF MEMBERS.— 

5 ‘‘(1) IN GENERAL.—The President, by and with 

6 the advice and consent of the Senate, shall appoint, 

7 without regard to political affiliation, 9 individuals 

8 who are citizens of the United States to serve as 

9 members of the Board for not more than 2 terms of 

10 4 years each, including— 

11 ‘‘(A) the Executive Director appointed 

12 under section 7903(a); 

13 ‘‘(B) 5 nongovernmental scientists in a life 

14 sciences field; and 

15 ‘‘(C) 2 nongovernmental national security 

16 experts. 

17 ‘‘(2) PERIOD FOR NOMINATIONS.—The Presi18 dent shall make nominations to the Board not later 

19 than 30 days after the date of enactment of this 

20 chapter. If the Senate votes not to confirm a nomi21 nation to the Board, the President shall make an 

22 additional nomination not later than 10 days after 

23 such vote by the Senate. 

24 ‘‘(3) CONSIDERATIONS OF RECOMMENDA25 TIONS.—The President shall make nominations to 


ssavage on LAPJG3WLY3PROD with BILLS
9 

•S 4667 RS

1 the Board after considering individuals rec2 ommended by the Chair and Ranking Member of the 

3 appropriate congressional committees. 

4 ‘‘(4) QUALIFICATIONS.—Individuals nominated 

5 to the Board— 

6 ‘‘(A) shall— 

7 ‘‘(i) be impartial individuals; and 

8 ‘‘(ii) be distinguished individuals of 

9 high national professional reputation in 

10 their respective fields who are capable of 

11 exercising the independent and objective 

12 judgment necessary to conduct an impar13 tial assessment of the potential risks and 

14 benefits associated with Federal funding of 

15 life sciences research to public health and 

16 national security; and 

17 ‘‘(B) may not be an employee of the Fed18 eral Government on the date of the appoint19 ment or during the 3-year period preceding the 

20 date of the appointment. 

21 ‘‘(5) LIMITATIONS.—Not more than 4 concur22 rent members of the Board may be employed by, a 

23 subcontractor of, a previous employee of, or a pre24 vious subcontractor of— 

25 ‘‘(A) the Department of Defense; 


ssavage on LAPJG3WLY3PROD with BILLS
10 

•S 4667 RS

1 ‘‘(B) the Department of Homeland Secu2 rity; 

3 ‘‘(C) the National Institute of Allergy and 

4 Infectious Diseases of the Department of 

5 Health and Human Services; 

6 ‘‘(D) the Office of the Director of National 

7 Intelligence; or 

8 ‘‘(E) the Department of Energy. 

9 ‘‘(6) CONSIDERATION BY THE SENATE.— 

10 ‘‘(A) IN GENERAL.—Nominations for ap11 pointment to the Board shall be referred to the 

12 Committee on Homeland Security and Govern13 mental Affairs of the Senate for consideration. 

14 ‘‘(B) RENOMINATION.—A member of the 

15 Board who is recommended to serve a second 

16 term shall be nominated for appointment to the 

17 Board, and such nomination shall be referred 

18 pursuant to subparagraph (A). 

19 ‘‘(7) VACANCY.—Not later than 30 days after 

20 the date on which a vacancy on the Board occurs, 

21 the vacancy shall be filled in the same manner as 

22 specified for the original appointment. 

23 ‘‘(8) REMOVAL.— 


ssavage on LAPJG3WLY3PROD with BILLS
11 

•S 4667 RS

1 ‘‘(A) IN GENERAL.—No member of the 

2 Board shall be removed from office, other than 

3 by— 

4 ‘‘(i) impeachment and conviction; 

5 ‘‘(ii) the action of the President for 

6 inefficiency, neglect of duty, malfeasance in 

7 office, physical disability, mental inca8 pacity, or any other condition that sub9 stantially impairs the performance of the 

10 member’s duties; or 

11 ‘‘(iii) the Board in accordance with 

12 subparagraph (B). 

13 ‘‘(B) ACTION BY BOARD.—If the Director 

14 of the Office of Government Ethics determines 

15 that participation by a member of the Board in 

16 high-risk life sciences research constitutes a 

17 conflict of interest, the Board shall take steps 

18 to mitigate or manage the conflict, which may 

19 include removal. 

20 ‘‘(C) NOTICE OF REMOVAL BY PRESI21 DENT.— 

22 ‘‘(i) IN GENERAL.—In the case of the 

23 removal of a member of the Board by the 

24 President as described in subparagraph 

25 (A)(ii), not later than 10 days after the reVerDate Sep 11 2014 00:24 Dec 06, 2024 Jkt 059200 PO 00000 Frm 00011 Fmt 6652 Sfmt 6401 E:\BILLS\S4667.RS S4667

ssavage on LAPJG3WLY3PROD with BILLS
12 

•S 4667 RS

1 moval, the President shall submit to the 

2 Chair and Ranking Members of the appro3 priate congressional committees a report 

4 specifying the facts found and the grounds 

5 for removal. 

6 ‘‘(ii) PUBLICATION OF REPORT.—The 

7 President shall publish in the Federal Reg8 ister each report submitted under clause 

9 (i), except that the President may, if nec10 essary to protect the rights of a person 

11 named in the report or to prevent undue 

12 interference with any pending prosecution, 

13 postpone or refrain from publicly pub14 lishing any or all of the report until the 

15 completion of such pending cases or pursu16 ant to privacy protection requirements in 

17 law. 

18 ‘‘(c) MANDATORY CONFLICTS OF INTEREST RE19 VIEW.— 

20 ‘‘(1) IN GENERAL.—The Director of the Office 

21 of Government Ethics shall— 

22 ‘‘(A) not later than 180 days after the date 

23 of the enactment of this chapter, and upon an 

24 appointment of a member to the Board under 

25 subsection (a)(1) thereafter, conduct a review of 


ssavage on LAPJG3WLY3PROD with BILLS
13 

•S 4667 RS

1 each individual nominated and appointed to the 

2 Board to ensure such individual does not have 

3 any conflict of interest; and 

4 ‘‘(B) periodically thereafter, conduct a re5 view of each individual nominated and ap6 pointed to the Board to ensure the individual 

7 does not have any conflict of interest during the 

8 term of service of the individual. 

9 ‘‘(2) NOTIFICATION.— 

10 ‘‘(A) IN GENERAL.—Not later than 3 days 

11 after the date on which the Director of the Of12 fice of Government Ethics becomes aware that 

13 a member of the Board possesses a potential 

14 conflict of interest to the mission of the Board, 

15 the Director shall notify the Chair and Ranking 

16 Members of the appropriate congressional com17 mittees of the potential conflict of interest. 

18 ‘‘(B) NOTIFICATION BY MEMBER.—Not 

19 later than 30 days after the date on which a 

20 member of the Board becomes aware that an21 other member of the Board possesses a poten22 tial conflict of interest to the mission of the 

23 Board, the member of the Board or the Execu24 tive Director of the Board shall notify the Chair 

25 and Ranking Members of the appropriate conVerDate Sep 11 2014 00:24 Dec 06, 2024 Jkt 059200 PO 00000 Frm 00013 Fmt 6652 Sfmt 6401 E:\BILLS\S4667.RS S4667

ssavage on LAPJG3WLY3PROD with BILLS
14 

•S 4667 RS

1 gressional committees of the potential conflict 

2 of interest. 

3 ‘‘(d) SECURITY CLEARANCES.—All members of the 

4 Board shall be granted all the necessary security clear5 ances and accesses, including to relevant Presidential and 

6 department or agency special access and compartmented 

7 access programs, in an accelerated manner subject to the 

8 standard procedures for granting such clearances. All 

9 nominees for appointment to the Board shall qualify for 

10 the necessary security clearances and accesses prior to 

11 being considered for confirmation by the Committee on 

12 Homeland Security and Governmental Affairs of the Sen13 ate. 

14 ‘‘(e) PARTICIPATION IN HIGH-RISK LIFE SCIENCES

15 RESEARCH.— 

16 ‘‘(1) DISCLOSURE REQUIRED.—A member of 

17 the Board shall disclose whether the member has 

18 participated in or is currently participating in high19 risk life sciences research. 

20 ‘‘(2) CONFLICTS OF INTEREST.— 

21 ‘‘(A) IN GENERAL.—The participation in 

22 high-risk life sciences research by a member of 

23 the Board— 

24 ‘‘(i) shall be considered a potential 

25 conflict of interest; and 


ssavage on LAPJG3WLY3PROD with BILLS
15 

•S 4667 RS

1 ‘‘(ii) shall be subject to scrutiny by 

2 the Director of the Office of Government 

3 Ethics. 

4 ‘‘(B) DETERMINATION.—If the Director of 

5 the Office of Government Ethics determines 

6 that participation by a member of the Board in 

7 high-risk life sciences research constitutes a 

8 conflict of interest, the Board shall take steps 

9 to mitigate or manage the conflict, which may 

10 include— 

11 ‘‘(i) the recusal of the affected mem12 ber from relevant discussions and deter13 minations; and 

14 ‘‘(ii) removal of the affected member 

15 from the Board. 

16 ‘‘(f) COMPENSATION OF MEMBERS.— 

17 ‘‘(1) IN GENERAL.—Subject to such rules as 

18 may be adopted by the Board, without regard to the 

19 provisions of title 5 governing appointments in the 

20 competitive service and without regard to the provi21 sions of chapter 51 and subchapter III of chapter 53 

22 of that title relating to classification and General 

23 Schedule pay rates, a member of the Board, other 

24 than the Executive Director, shall be compensated at 

25 a rate— 


ssavage on LAPJG3WLY3PROD with BILLS
16 

•S 4667 RS

1 ‘‘(A) proposed by the Executive Director 

2 and approved by the Board; 

3 ‘‘(B) not to exceed the rate of basic pay 

4 for level II of the Executive Schedule; and 

5 ‘‘(C) that is commensurate with— 

6 ‘‘(i) the time a member of the Board 

7 spends engaged in the performance of du8 ties on the Board; and 

9 ‘‘(ii) necessary traveling expenses. 

10 ‘‘(2) OUTSIDE EMPLOYMENT.—Subject to terms 

11 and approval determined by the Director of the Of12 fice of Government Ethics, a member of the Board 

13 may maintain outside employment and affiliations 

14 while serving on the Board. 

15 ‘‘(g) OVERSIGHT.— 

16 ‘‘(1) SENATE.—The Committee on Homeland 

17 Security and Governmental Affairs of the Senate 

18 shall— 

19 ‘‘(A) have continuing legislative oversight 

20 jurisdiction in the Senate with respect to the of21 ficial conduct of the Board and agency compli22 ance with requirements issued by the Board; 

23 and 

24 ‘‘(B) have access to any records provided 

25 to or created by the Board. 


ssavage on LAPJG3WLY3PROD with BILLS
17 

•S 4667 RS

1 ‘‘(2) HOUSE OF REPRESENTATIVES.—The Com2 mittee on Oversight and Accountability of the House 

3 of Representatives shall— 

4 ‘‘(A) have continuing legislative oversight 

5 jurisdiction in the House of Representatives 

6 with respect to the official conduct of the Board 

7 and agency compliance with requirements 

8 issued by the Board; and 

9 ‘‘(B) have access to any records provided 

10 to or created by the Board. 

11 ‘‘(3) DUTY TO COOPERATE.—The Board shall 

12 have the duty to cooperate with the exercise of over13 sight jurisdiction described in this subsection. 

14 ‘‘(4) SECURITY CLEARANCES.—The Chair and 

15 Ranking Members of the appropriate congressional 

16 committees, and designated committee staff, shall be 

17 granted all security clearances and accesses held by 

18 the Board, including to relevant Presidential and de19 partment or agency special access and compart20 mented access programs. 

21 ‘‘(h) OFFICE SPACE.—In selecting office space for 

22 the Board, the Board shall exhaust options for unused of23 fice spaces owned by the Federal Government as of the 

24 date of enactment of this chapter. 


ssavage on LAPJG3WLY3PROD with BILLS
18 

•S 4667 RS

1 ‘‘§ 7903. Board personnel 

2 ‘‘(a) EXECUTIVE DIRECTOR.— 

3 ‘‘(1) APPOINTMENT.—Not later than 45 days 

4 after the date of the enactment of this chapter, the 

5 President shall appoint 1 individual who is a citizen 

6 of the United States, without regard to political af7 filiation, to the position of Executive Director of the 

8 Board for a term of 4 years. 

9 ‘‘(2) QUALIFICATIONS.—The individual ap10 pointed as Executive Director under paragraph (1) 

11 shall be a private individual of integrity and impar12 tiality who— 

13 ‘‘(A) is a distinguished scientist in a life 

14 sciences field; and 

15 ‘‘(B) is not, and has not been for the 3- 

16 year period preceding the date of the appoint17 ment— 

18 ‘‘(i) an employee of the Federal Gov19 ernment; or 

20 ‘‘(ii) a participant in high-risk life 

21 sciences research supported by Federal 

22 funding. 

23 ‘‘(3) SECURITY CLEARANCES.— 

24 ‘‘(A) IN GENERAL.—A candidate for Exec25 utive Director shall be granted all security 

26 clearances and accesses held by the Board, inVerDate Sep 11 2014 00:24 Dec 06, 2024 Jkt 059200 PO 00000 Frm 00018 Fmt 6652 Sfmt 6401 E:\BILLS\S4667.RS S4667

ssavage on LAPJG3WLY3PROD with BILLS
19 

•S 4667 RS

1 cluding to relevant Presidential and department 

2 or agency special access and compartmented ac3 cess programs in an accelerated manner, sub4 ject to the standard procedures for granting 

5 such clearances. 

6 ‘‘(B) QUALIFICATION PRIOR TO APPOINT7 MENT.—The President shall ensure that a can8 didate for Executive Director qualifies for the 

9 security clearances and accesses described in 

10 subparagraph (A) prior to appointment. 

11 ‘‘(4) FUNCTIONS.—The Executive Director 

12 shall— 

13 ‘‘(A) serve as principal liaison to Congress 

14 and agencies; 

15 ‘‘(B) serve as Chair of the Board; 

16 ‘‘(C) be responsible for the administration 

17 and coordination of the responsibilities of the 

18 Board; and 

19 ‘‘(D) be responsible for the administration 

20 of all official activities conducted by the Board. 

21 ‘‘(5) REMOVAL.—Notwithstanding section 

22 7902(b)(8), the Executive Director shall not be re23 moved for reasons other than for cause on the 

24 grounds of inefficiency, neglect of duty, malfeasance 

25 in office, physical disability, mental incapacity, or 


ssavage on LAPJG3WLY3PROD with BILLS
20 

•S 4667 RS

1 any other condition that substantially impairs the 

2 performance of the responsibilities of the Executive 

3 Director or the staff of the Board. 

4 ‘‘(6) TERMS.—An Executive Director shall not 

5 serve more than 2 terms. 

6 ‘‘(b) STAFF.— 

7 ‘‘(1) IN GENERAL.—The Board, without regard 

8 to the civil service laws, may appoint additional per9 sonnel as necessary to enable the Board and the Ex10 ecutive Director to perform the duties of the Board. 

11 ‘‘(2) QUALIFICATIONS.—Each individual ap12 pointed to the staff of the Board— 

13 ‘‘(A) shall be a citizen of the United States 

14 of integrity and impartiality; 

15 ‘‘(B) shall have expertise in the life 

16 sciences field or the national security field; and 

17 ‘‘(C) may not be a participant in any fed18 erally funded research activity on the date of 

19 the appointment or during the course of service 

20 of the individual on the Board. 

21 ‘‘(3) SECURITY CLEARANCES.— 

22 ‘‘(A) IN GENERAL.—A candidate for ap23 pointment to the staff of the Board shall be 

24 granted all security clearances and accesses 

25 held by the Board, including to relevant PresiVerDate Sep 11 2014 00:24 Dec 06, 2024 Jkt 059200 PO 00000 Frm 00020 Fmt 6652 Sfmt 6401 E:\BILLS\S4667.RS S4667

ssavage on LAPJG3WLY3PROD with BILLS
21 

•S 4667 RS

1 dential and department or agency special access 

2 and compartmented access programs, in an ac3 celerated manner, subject to the standard pro4 cedures for granting such clearances. 

5 ‘‘(B) CONDITIONAL EMPLOYMENT.— 

6 ‘‘(i) IN GENERAL.—The Board may 

7 offer conditional employment to a can8 didate for a staff position of the Board 

9 pending the completion of security clear10 ance background investigations. During 

11 the pendency of such investigations, the 

12 Board shall ensure that any such employee 

13 does not have access to, or responsibility 

14 involving, classified or otherwise restricted 

15 materials. 

16 ‘‘(ii) UNQUALIFIED STAFF.—If an in17 dividual hired on a conditional basis under 

18 clause (i) is denied or otherwise does not 

19 qualify for all security clearances necessary 

20 to carry out the responsibilities of the posi21 tion for which conditional employment has 

22 been offered, the Board shall immediately 

23 terminate the individual’s employment. 

24 ‘‘(4) SUPPORT FROM AGENCIES.— 


ssavage on LAPJG3WLY3PROD with BILLS
22 

•S 4667 RS

1 ‘‘(A) IN GENERAL.—The head of each 

2 agency shall designate not less than 1 full-time 

3 employee of the agency as the representative of 

4 the agency to— 

5 ‘‘(i) provide technical assistance to the 

6 Board; and 

7 ‘‘(ii) support the review process of the 

8 Board with respect to the agency under 

9 section 7906 in a non-voting staff capacity. 

10 ‘‘(B) PROHIBITION.—A representative des11 ignated under subparagraph (A) and any em12 ployee of an agency may not directly or indi13 rectly influence in any capacity a determination 

14 by the Board under section 7906 with respect 

15 to life sciences research funded by the agency. 

16 ‘‘(c) COMPENSATION.—Subject to such rules as may 

17 be adopted by the Board, without regard to the provisions 

18 of title 5 governing appointments in the competitive serv19 ice and without regard to the provisions of chapter 51 and 

20 subchapter III of chapter 53 of that title relating to classi21 fication and General Schedule pay rates, the Executive Di22 rector shall— 

23 ‘‘(1) be compensated at a rate not to exceed the 

24 rate of basic pay for level II of the Executive Sched25 ule; 


ssavage on LAPJG3WLY3PROD with BILLS
23 

•S 4667 RS

1 ‘‘(2) serve the entire tenure as Executive Direc2 tor as one full-time employee; and 

3 ‘‘(3) appoint and fix the compensation of such 

4 other personnel as may be necessary to carry out 

5 this chapter. 

6 ‘‘§ 7904. Board mission and functions 

7 ‘‘(a) MISSION.—The mission of the Board shall be 

8 to issue an independent determination as to whether an 

9 agency may award Federal funding for proposed life 

10 sciences research, which shall be binding upon the agency. 

11 ‘‘(b) POWERS.—The Board shall have the authority 

12 to act in a manner to carry out the mission described in 

13 subsection (a), including authority to— 

14 ‘‘(1) prescribe regulations to carry out the re15 sponsibilities of the Board; 

16 ‘‘(2) establish a process for the review of Fed17 eral funding for life sciences research prior to the 

18 award of the Federal funding, which shall be binding 

19 upon an agency, including information designated as 

20 classified or otherwise protected from disclosure; 

21 ‘‘(3) direct an agency to make available to the 

22 Board additional information and records, including 

23 information designated as classified or otherwise 

24 protected from disclosure, that the Board determines 


ssavage on LAPJG3WLY3PROD with BILLS
24 

•S 4667 RS

1 are required to fulfill the functions and responsibil2 ities Board under this chapter; 

3 ‘‘(4) review any classified research conducted or 

4 funded by any agency to determine whether the re5 search would be considered high-risk life sciences re6 search; 

7 ‘‘(5) through the promulgation of regulations, 

8 establish processes, policies, and procedures of the 

9 Board for rendering decisions under this chapter; 

10 and 

11 ‘‘(6) by majority vote, add an agent or toxin to 

12 the definition of ‘agent or toxin’ under section 7901. 

13 ‘‘(c) INITIAL REQUIREMENTS.—The Board shall— 

14 ‘‘(1) not later than 90 days after the date of 

15 appointment of the initial members of the Board 

16 under section 7902, publish procedures in the Fed17 eral Register establishing the process for the review 

18 by the Board under section 7906 ; 

19 ‘‘(2) prior to the establishment of the proce20 dures under paragraph (1), consult with the appro21 priate congressional committees and heads of agen22 cies for purposes of developing such procedures; and 

23 ‘‘(3) not later than 180 days after the date of 

24 the enactment of this chapter, begin carrying out the 

25 duties described in section 7906. 


ssavage on LAPJG3WLY3PROD with BILLS
25 

•S 4667 RS

1 ‘‘(d) RESPONSIVENESS TO CONGRESS.—Notwith2 standing any other provision of law, not later than 30 days 

3 after the date on which the Board receives a request for 

4 information from a Member of Congress, the Board shall 

5 respond to the request. 

6 ‘‘(e) CONGRESSIONAL BRIEFINGS.—Not less fre7 quently than quarterly, the Board shall brief the appro8 priate congressional committees on the work of the Board. 

9 ‘‘§ 7905. Agency procedures; referral to Board 

10 ‘‘(a) IN GENERAL.—Beginning 180 days after the 

11 date of enactment of this chapter, the head of an agency— 

12 ‘‘(1) may not award Federal funding for high13 risk life sciences research without approval by the 

14 Board under section 7906(a)(1)(B); and 

15 ‘‘(2) may not award Federal funding for life 

16 sciences research disapproved of by the Board under 

17 section 7906(a)(2)(A)(i)(II). 

18 ‘‘(b) HIGH-RISK ATTESTATION; SELECT AGENT OR

19 TOXIN DISCLOSURE; CERTIFICATION.— 

20 ‘‘(1) IN GENERAL.—An entity seeking Federal 

21 funding from an agency for life sciences research 

22 shall, under the penalty of perjury— 

23 ‘‘(A) attest whether— 

24 ‘‘(i) the life sciences research will con25 stitute high-risk life sciences research; and 


ssavage on LAPJG3WLY3PROD with BILLS
26 

•S 4667 RS

1 ‘‘(ii) the entity is performing active 

2 research with a select agent or toxin; and 

3 ‘‘(B) if the entity is makes a positive attes4 tation under subparagraph (A), disclose the 

5 source of funding for all active research. 

6 ‘‘(2) ACTIVE RESEARCH WITH SELECT AGENTS

7 OR TOXINS.— 

8 ‘‘(A) IN GENERAL.—The head of an agen9 cy that receives a disclosure from an entity 

10 under paragraph (1)(B) shall submit to the 

11 Board the disclosure. 

12 ‘‘(B) BOARD INQUIRIES.—The Board may 

13 contact an entity that submits a disclosure 

14 under paragraph (1)(B) to request additional 

15 information relating to the disclosure. 

16 ‘‘(3) AGENCY CERTIFICATION.— 

17 ‘‘(A) POSITIVE ATTESTATIONS.—The head 

18 of an agency making an award of Federal fund19 ing to an entity that makes a positive attesta20 tion under paragraph (1)(A)(i) shall— 

21 ‘‘(i) submit to the Board the high-risk 

22 life sciences proposal; and 

23 ‘‘(ii) using the process established by 

24 the head of the agency under paragraph 

25 (4), certify the validity of the attestation. 


ssavage on LAPJG3WLY3PROD with BILLS
27 

•S 4667 RS

1 ‘‘(B) NEGATIVE ATTESTATIONS.—The 

2 head of an agency making an award of Federal 

3 funding to an entity that makes a negative at4 testation under paragraph (1)(A)(i) shall— 

5 ‘‘(i) review the attestation; and 

6 ‘‘(ii) using the process established by 

7 the head of the agency under paragraph 

8 (4), certify the validity of the attestation. 

9 ‘‘(4) PROCESS FOR REVIEW.—The head of each 

10 agency that awards Federal funding for life sciences 

11 research, in consultation with the Board, shall estab12 lish and implement a process for identifying pro13 posals from entities seeking Federal funding for life 

14 sciences research from the agency that will con15 stitute high-risk life sciences research. 

16 ‘‘(5) MAINTENANCE OF RECORDS.—The head of 

17 each agency shall— 

18 ‘‘(A) maintain records of the certification 

19 process described in paragraph (3)(B) for each 

20 application for Federal funding; and 

21 ‘‘(B) make the records maintained under 

22 subparagraph (A) available for audit and review 

23 upon request by the Board. 

24 ‘‘(c) NOTIFICATION.— 


ssavage on LAPJG3WLY3PROD with BILLS
28 

•S 4667 RS

1 ‘‘(1) IN GENERAL.—Not later than 30 days be2 fore the date on which the head of an agency plans 

3 to award Federal funding to an entity for life 

4 sciences research, the head of the agency shall sub5 mit to the Board a notification of the proposed Fed6 eral funding for review under section 7906(a). 

7 ‘‘(2) CONTENTS.—The notification of Federal 

8 funding for life sciences research required under 

9 paragraph (1) shall include the attestation and cer10 tification required under subsection (b). 

11 ‘‘(d) AGENCY PROCEDURES.—Not later than 180 

12 days after the date on which the Board publishes the proc13 ess of the Board in the Federal Register pursuant to sec14 tion 7904(c), the head of each agency shall publish on the 

15 website of the agency prepayment and preaward proce16 dures of the agency with respect to Federal funding for 

17 life sciences research to— 

18 ‘‘(1) guarantee that— 

19 ‘‘(A) all life science research proposals are 

20 referred to the Board before the award of Fed21 eral funding by the agency; and 

22 ‘‘(B) no Federal funding for high-risk life 

23 sciences research is awarded by the agency 

24 without approval by the Board; and 


ssavage on LAPJG3WLY3PROD with BILLS
29 

•S 4667 RS

1 ‘‘(2) otherwise ensure compliance with this 

2 chapter. 

3 ‘‘(e) PROVISION OF ADDITIONAL INFORMATION.— 

4 Upon request by the Board, the head of an agency shall 

5 provide any information relating to Federal funding 

6 awards for life sciences research determined necessary by 

7 the Board to provide oversight of the agency. 

8 ‘‘(f) CHANGE IN CIRCUMSTANCES DURING RE9 SEARCH.—If, during the course of life sciences research 

10 in progress performed by an entity supported by Federal 

11 funding from an agency, circumstances arise such that the 

12 life sciences research in progress may constitute high-risk 

13 life sciences research in contravention to the attestation 

14 of the entity under subsection (b)(1)(A)(i)— 

15 ‘‘(1) the entity shall— 

16 ‘‘(A) pause the life sciences research in 

17 progress; and 

18 ‘‘(B) notify the head of the agency of the 

19 possibility that the life sciences research in 

20 progress may constitute high-risk life sciences 

21 research; and 

22 ‘‘(2) the head of the agency shall— 

23 ‘‘(A) using the process of the agency estab24 lished under subsection (b)(4), determine 


ssavage on LAPJG3WLY3PROD with BILLS
30 

•S 4667 RS

1 whether the life sciences research in progress 

2 constitutes high-risk life sciences research; 

3 ‘‘(B) if the head of the agency makes a 

4 negative determination under subparagraph 

5 (A), inform the entity that the entity may re6 sume the life sciences research in progress; and 

7 ‘‘(C) if the head of the agency makes a 

8 positive determination under subparagraph (A), 

9 immediately submit to the Board a notification 

10 of the Federal funding of high-risk life sciences 

11 research in progress for review under section 

12 7906(a)(1). 

13 ‘‘(g) ENFORCEMENT.— 

14 ‘‘(1) APPLICANT REQUIREMENTS.—If an entity 

15 seeking or receiving Federal funding from an agency 

16 fails to make a true attestation under subsection 

17 (b)(1) or promptly notify the agency of changes de18 scribed in subsection (f), the inspector general of the 

19 agency may permanently disqualify the entity from 

20 receiving any Federal funding. 

21 ‘‘(2) REFERRAL TO ATTORNEY GENERAL.—The 

22 Board shall refer any official of an agency respon23 sible for overseeing and reviewing research proposals 

24 relating to Federal funding that fails to comply with 


ssavage on LAPJG3WLY3PROD with BILLS
31 

•S 4667 RS

1 subsection (b)(3) to the inspector general of the 

2 agency. 

3 ‘‘(3) EMPLOYEE DISCIPLINE.— 

4 ‘‘(A) IN GENERAL.—Notwithstanding any 

5 provision of title 5, and subject to subpara6 graph (B), the head of an agency employing an 

7 employee who violates any provision of sub8 section (b)(3) (or, in the case of the head of an 

9 agency who violates any provision of subsection 

10 (b)(3), the President) shall impose on that em11 ployee— 

12 ‘‘(i) disciplinary action consisting of 

13 removal, reduction in grade, suspension, or 

14 debarment from employment with the 

15 United States; 

16 ‘‘(ii) a civil penalty in an amount that 

17 is not less than $10,000; 

18 ‘‘(iii) ineligibility for any annuity 

19 under chapter 83 or 84 of title 5; and 

20 ‘‘(iv) permanent revocation of any ap21 plicable security clearance held by the em22 ployee. 

23 ‘‘(B) SPECIFIC CONTRACTOR DIS24 CIPLINE.—In the case of an individual de25 scribed in section 7901(5) working under a conVerDate Sep 11 2014 00:24 Dec 06, 2024 Jkt 059200 PO 00000 Frm 00031 Fmt 6652 Sfmt 6401 E:\BILLS\S4667.RS S4667

ssavage on LAPJG3WLY3PROD with BILLS
32 

•S 4667 RS

1 tract with an agency who violates any provision 

2 of subsection (b)(2), in addition to any dis3 cipline that may be applicable under subpara4 graph (A) of this paragraph, that individual 

5 shall be barred from working under any con6 tract with the Federal Government. 

7 ‘‘(C) EMPLOYEE DISCIPLINE REPORTS.— 

8 ‘‘(i) IN GENERAL.—Not later than 

9 360 days after the date of enactment of 

10 this Act, and not less frequently than once 

11 every 90 days thereafter, the head of each 

12 agency shall submit to the Board and the 

13 appropriate congressional committees a re14 port that discloses, for the period covered 

15 by the report, each violation by an em16 ployee of the agency of subsection (b)(3). 

17 ‘‘(ii) CONTENTS.—Each report sub18 mitted under clause (i) shall include, with 

19 respect to a violation described in that 

20 clause— 

21 ‘‘(I) the name and professional 

22 title of each employee engaged in the 

23 violation; 

24 ‘‘(II) a detailed explanation of 

25 the nature of the violation; and 


ssavage on LAPJG3WLY3PROD with BILLS
33 

•S 4667 RS

1 ‘‘(III) the date of the violation. 

2 ‘‘(iii) PUBLICATION.—Not later than 

3 5 days after the date on which the Board 

4 receives a report under clause (i), the 

5 Board shall— 

6 ‘‘(I) collect the report and assign 

7 the report a unique tracking number; 

8 and 

9 ‘‘(II) publish on a publicly acces10 sible and searchable website the con11 tents of the report and the tracking 

12 number for the report. 

13 ‘‘(h) SUBAWARD AND SUBCONTRACTOR DISCLO14 SURE.— 

15 ‘‘(1) IN GENERAL.—During the course of life 

16 sciences research in progress performed by an entity 

17 supported by Federal funding from an agency, the 

18 entity shall continuously disclose to the head of the 

19 agency any subcontracts or subawards made with 

20 the Federal funding. 

21 ‘‘(2) AGENCY SUBMISSION.—Not later than 30 

22 days after the date on which the head of an agency 

23 receives a disclosure under paragraph (1), the head 

24 of the agency shall submit to the Board the disclo25 sure. 


ssavage on LAPJG3WLY3PROD with BILLS
34 

•S 4667 RS

1 ‘‘(3) BOARD INQUIRIES.— 

2 ‘‘(A) IN GENERAL.—The Board may con3 tact an entity that submits a disclosure under 

4 paragraph (1) to request additional information 

5 relating to the disclosure. 

6 ‘‘(B) ACCESS TO REPORTS.—During the 

7 course of life sciences research in progress per8 formed by an entity supported by Federal fund9 ing from an agency, upon request, the Board 

10 shall have access to every annual report— 

11 ‘‘(i) of the agency; 

12 ‘‘(ii) of the entity performing the life 

13 sciences research; and 

14 ‘‘(iii) of any subawardee of an entity 

15 described in clause (ii). 

16 ‘‘§ 7906. Board review 

17 ‘‘(a) IN GENERAL.— 

18 ‘‘(1) HIGH-RISK LIFE SCIENCES RESEARCH.— 

19 Not later than 120 days after the date on which the 

20 Board receives a notification from an agency under 

21 section 7905(c) relating to proposed Federal funding 

22 for life sciences research that constitutes high-risk 

23 life sciences research or a notification from an agen24 cy under section 7905(f)(2)(C) relating to Federal 


ssavage on LAPJG3WLY3PROD with BILLS
35 

•S 4667 RS

1 funding of research in progress that constitutes 

2 high-risk life sciences research, the Board shall— 

3 ‘‘(A) review the proposed Federal funding 

4 or research in progress; 

5 ‘‘(B) by a majority vote, determine wheth6 er the agency may award the proposed Federal 

7 funding or continue to award the Federal fund8 ing for the research in progress; and 

9 ‘‘(C) by a majority vote, determine with re10 spect to the life sciences research funded by the 

11 proposed Federal funding or Federal funding 

12 for research in progress— 

13 ‘‘(i) the minimum required biosafety 

14 containment level, engineering controls, 

15 and operational controls; 

16 ‘‘(ii) the minimum required biosecu17 rity engineering controls and operational 

18 controls; and 

19 ‘‘(iii) the minimum required personnel 

20 assurance controls. 

21 ‘‘(2) LIFE SCIENCES RESEARCH.— 

22 ‘‘(A) PROPOSED FUNDING.— 

23 ‘‘(i) IN GENERAL.—With respect to 

24 proposed Federal funding by an agency for 

25 life sciences research that does not conVerDate Sep 11 2014 00:24 Dec 06, 2024 Jkt 059200 PO 00000 Frm 00035 Fmt 6652 Sfmt 6401 E:\BILLS\S4667.RS S4667

ssavage on LAPJG3WLY3PROD with BILLS
36 

•S 4667 RS

1 stitute high-risk life sciences research, the 

2 Board may— 

3 ‘‘(I) review the proposed Federal 

4 funding; and 

5 ‘‘(II) by a majority vote, deter6 mine whether the agency may award 

7 the proposed Federal funding. 

8 ‘‘(ii) NOTIFICATION.—If the Board 

9 determines not to permit the award of 

10 Federal funding proposed by an agency 

11 pursuant to clause (i)(II), the Board shall 

12 notify the head of the agency and identify 

13 the factors that contributed to the deter14 mination of the Board. 

15 ‘‘(B) PAST FUNDING.—With respect to 

16 Federal funding that has already been awarded 

17 by an agency for life sciences research that does 

18 not constitute high-risk life sciences research, 

19 the Board may review and audit the life 

20 sciences research. 

21 ‘‘(b) CONSIDERATIONS.— 

22 ‘‘(1) IN GENERAL.—In making a determination 

23 under paragraph (1)(B) and (2)(A)(i)(II) of sub24 section (a), the Board shall consider, with respect to 

25 the life sciences research that will be conducted with 


ssavage on LAPJG3WLY3PROD with BILLS
37 

•S 4667 RS

1 the proposed Federal funding or research in 

2 progress— 

3 ‘‘(A) whether the research poses a threat 

4 to public health; 

5 ‘‘(B) whether the research poses a threat 

6 to public safety; 

7 ‘‘(C) whether the research has a high prob8 ability of producing benefits for public health; 

9 ‘‘(D) whether the research poses a threat 

10 to large populations of animals, and plants; 

11 ‘‘(E) whether the research poses a threat 

12 to national security; 

13 ‘‘(F) whether the research is proposed to 

14 be conducted in a foreign country; 

15 ‘‘(G) the reasonably anticipated material 

16 risks; 

17 ‘‘(H) the reasonably anticipated informa18 tion risks; 

19 ‘‘(I) the reasonably anticipated benefits; 

20 ‘‘(J) whether the reasonably anticipated 

21 benefits outweigh the reasonably anticipated 

22 risks; and 

23 ‘‘(K) whether the benefits could be ob24 tained through procedures posing lower risks. 


ssavage on LAPJG3WLY3PROD with BILLS
38 

•S 4667 RS

1 ‘‘(2) WEIGHT OF FACTORS.—The presence or 

2 absence of any factor under paragraph (1) shall not 

3 be decisive with respect to the determination of the 

4 Board under paragraph (1)(B) and (2)(A)(i)(II) of 

5 subsection (a). 

6 ‘‘(c) NOTICE FOLLOWING REVIEW AND DETERMINA7 TION.— 

8 ‘‘(1) AGENCY NOTIFICATION.—Not later than 5 

9 days after the date on which the Board makes a de10 termination under subsection (a)(1)(B), the Execu11 tive Director of the Board shall notify the head of 

12 the agency of the determination. 

13 ‘‘(2) NOTIFICATION TO APPROPRIATE CONGRES14 SIONAL COMMITTEES.—If the Board determines that 

15 the head of an agency may not proceed with an 

16 award of proposed Federal funding under this sec17 tion, the Executive Director of the Board shall no18 tify the appropriate congressional committees when 

19 the Board notifies the head of the agency. 

20 ‘‘(d) BOARD DELEGATION OF DECISIONMAKING TO

21 AUTHORIZED PERSONNEL.— 

22 ‘‘(1) IN GENERAL.—The Board may vote to del23 egate to designated personnel of the Board ap24 pointed under section 7903(b) the authority to de25 termine whether to review proposed Federal funding 


ssavage on LAPJG3WLY3PROD with BILLS
39 

•S 4667 RS

1 for life sciences research under subsection 

2 (a)(2)(A)(i)(I). 

3 ‘‘(2) POLICIES AND PROCEDURES.—The delega4 tion authorized under paragraph (1) shall be subject 

5 to policies and procedures— 

6 ‘‘(A) unanimously approved by the Board; 

7 ‘‘(B) established in consultation with the 

8 appropriate congressional committees; and 

9 ‘‘(C) published in the Federal Register. 

10 ‘‘(3) HIGH-RISK LIFE SCIENCES RESEARCH AP11 PROVAL.—The Board may not delegate the require12 ment to make a review and determination under 

13 subsection (a)(1)(i) with respect to Federal funding 

14 for high-risk life sciences research. 

15 ‘‘(e) SCIENTIFIC EXPERT PANELS.— 

16 ‘‘(1) IN GENERAL.—The Board may establish a 

17 scientific panel of experts to advise the Board in the 

18 review by the Board of life sciences research pursu19 ant to this chapter. 

20 ‘‘(2) POLICIES AND PROCEDURES.—The Board 

21 shall establish and publish in the Federal Register 

22 procedures and policies relating to conflicts of inter23 est, recusal, expertise, and related matters before 

24 the establishment of the panel described in para25 graph (1). 


ssavage on LAPJG3WLY3PROD with BILLS
40 

•S 4667 RS

1 ‘‘(3) PROHIBITION.—An individual serving on 

2 the panel established under paragraph (1) may not 

3 advise the Board on any matter with respect to 

4 which the individuals has an identified or perceived 

5 conflict of interest. 

6 ‘‘(4) REPORT.— 

7 ‘‘(A) IN GENERAL.—Not later than 30 

8 days after the date on which the Board estab9 lishes a panel established under paragraph (1), 

10 the Board shall submit to the appropriate con11 gressional committees a report that includes the 

12 names of individuals who serve on the panel. 

13 ‘‘(B) PANEL CHANGES.—Upon a change of 

14 personnel on the panel established under para15 graph (1), the Board shall immediately submit 

16 to the appropriate congressional committees an 

17 update to the report required under subpara18 graph (A). 

19 ‘‘(f) REPORT.—Not later than 360 days after the 

20 date on which the Board establishes the panel described 

21 in subsection (e)(1), and annually thereafter, the Board 

22 shall submit to the appropriate congressional committees 

23 and make available on a website a report summarizing, 

24 with respect to each determination by the Board under 

25 this section relating to life sciences research— 


ssavage on LAPJG3WLY3PROD with BILLS
41 

•S 4667 RS

1 ‘‘(1) the findings of the Board; 

2 ‘‘(2) the determination of the Board; 

3 ‘‘(3) the name and location of the entity pro4 posing the life sciences research; 

5 ‘‘(4) the name and location of any recipient of 

6 a subaward or subcontractor of an entity proposing 

7 life sciences research and the nature of the partici8 pation of such a recipient or subcontractor; and 

9 ‘‘(5) an account of significant challenges or 

10 problems, including procedural or substantive chal11 lenges or problems, that arise during the course of 

12 the work of the Board, including the views of any 

13 member of the Board who wishes to have those 

14 views included in the report. 

15 ‘‘(g) EFFECTIVE DATE.—This section shall take ef16 fect on the date that is 180 days after the date of enact17 ment of this chapter. 

18 ‘‘§ 7907. Funding 

19 ‘‘(a) AUTHORIZATION OF APPROPRIATIONS.—There 

20 is authorized to be appropriated to the Board to carry out 

21 this chapter $30,000,000 for each of fiscal years 2025 

22 through 2034. 

23 ‘‘(b) DHS TRANSFER.— 

24 ‘‘(1) IN GENERAL.—Subject to paragraph (2) 

25 and notwithstanding any other law, in any fiscal 


ssavage on LAPJG3WLY3PROD with BILLS
42 

•S 4667 RS

1 year for which amounts are authorized to be appro2 priated under subsection (a), of the amounts the 

3 Secretary of Homeland Security would otherwise 

4 award as grants, the Secretary of Homeland Secu5 rity shall transfer $30,000,000 to the Board. 

6 ‘‘(2) EXCEPTION.—A transfer under paragraph 

7 (1) shall not apply to amounts awarded as grants 

8 from the Disaster Relief Fund of the Federal Emer9 gency Management Agency.’’. 

10 (b) CLERICAL AMENDMENT.—The table of sections 

11 for subtitle V of title 31, United States Code, is amended 

12 by adding at the end the following: 

‘‘CHAPTER 79—LIFE SCIENCES RESEARCH SECURITY BOARD

‘‘7901. Definitions. 

‘‘7902. Establishment and membership. 

‘‘7903. Board personnel. 

‘‘7904. Board mission and functions. 

‘‘7905. Agency procedures; referral to Board. 

‘‘7906. Board review. 

‘‘7907. Funding.’’. 

13 (c) FINANCIAL DISCLOSURE REPORTS OF BOARD

14 MEMBERS.—Section 13103(f) of title 5, United States 

15 Code, is amended— 

16 (1) in paragraph (11), by striking ‘‘and’’ at the 

17 end; 

18 (2) in paragraph (12), by striking the period at 

19 the end and inserting ‘‘; and’’; and 

20 (3) by adding at the end the following: 


ssavage on LAPJG3WLY3PROD with BILLS
43 

•S 4667 RS

1 ‘‘(13) a member of the Life Sciences Research 

2 Security Board established under section 7902 of 

3 title 31.’’. 

4 SECTION 1. SHORT TITLE. 

5 This Act may be cited as the ‘‘Risky Research Review 

6 Act’’. 

7 SEC. 2. LIFE SCIENCES RESEARCH SECURITY BOARD. 

8 (a) IN GENERAL.—Subtitle V of title 31, United States 

9 Code, is amended by adding at the end the following: 

10 ‘‘CHAPTER 79—LIFE SCIENCES RESEARCH 

11 SECURITY BOARD 

‘‘7901. Definitions. 

‘‘7902. Establishment and membership. 

‘‘7903. Board personnel. 

‘‘7904. Board mission and functions. 

‘‘7905. Agency procedures; referral to Board. 

‘‘7906. Board review. 

‘‘7907. GAO Audits. 

‘‘7908. Funding. 

12 ‘‘§ 7901. Definitions 

13 ‘‘In this chapter: 

14 ‘‘(1) AGENCY.—The term ‘agency’ has the mean15 ing given the term in section 552(f) of title 5. 

16 ‘‘(2) APPROPRIATE CONGRESSIONAL COMMIT17 TEES.—The term ‘appropriate congressional commit18 tees’ means the Committee on Homeland Security and 

19 Governmental Affairs of the Senate and the Com20 mittee on Oversight and Accountability of the House 

21 of Representatives. 


ssavage on LAPJG3WLY3PROD with BILLS
44 

•S 4667 RS

1 ‘‘(3) BOARD.—The term ‘Board’ means the Life 

2 Sciences Research Security Board established under 

3 section 7902(a). 

4 ‘‘(4) DUAL USE RESEARCH OF CONCERN.—The 

5 term ‘dual use research of concern’— 

6 ‘‘(A) means life sciences research that, based 

7 on current understanding, can be reasonably an8 ticipated to provide knowledge, information, 

9 products, or technologies that could— 

10 ‘‘(i) be misapplied to do harm with no 

11 modification or only a minor modification; 

12 and 

13 ‘‘(ii) pose a significant threat with po14 tential consequences to public health and 

15 safety, agricultural crops and other plants, 

16 animals, materiel, or national security; and 

17 ‘‘(B) includes— 

18 ‘‘(i) life sciences research that could— 

19 ‘‘(I) increase transmissibility of a 

20 pathogen within or between host spe21 cies; 

22 ‘‘(II) increase the virulence of a 

23 pathogen or convey virulence to a non24 pathogen; 


ssavage on LAPJG3WLY3PROD with BILLS
45 

•S 4667 RS

1 ‘‘(III) increase the toxicity of a 

2 known toxin or produce a novel toxin; 

3 ‘‘(IV) increase— 

4 ‘‘(aa) the stability of a 

5 pathogen or toxin in the environ6 ment; or 

7 ‘‘(bb) the ability to dissemi8 nate a pathogen or toxin; 

9 ‘‘(V) alter the host range or tro10 pism of a pathogen or toxin; 

11 ‘‘(VI) decrease the ability for a 

12 human or veterinary pathogen or toxin 

13 to be detected using standard diag14 nostic or analytical methods; 

15 ‘‘(VII) increase resistance of a 

16 pathogen or toxin to clinical or veteri17 nary prophylactic or therapeutic inter18 ventions; 

19 ‘‘(VIII) alter a human or veteri20 nary pathogen or toxin to disrupt the 

21 effectiveness of pre-existing immunity, 

22 via immunization or natural infection, 

23 against the pathogen or toxin; 


ssavage on LAPJG3WLY3PROD with BILLS
46 

•S 4667 RS

1 ‘‘(IX) enhance the susceptibility of 

2 a host population to a pathogen or 

3 toxin; 

4 ‘‘(X) enhance transmissibility of a 

5 pathogen in humans; 

6 ‘‘(XI) enhance the virulence of a 

7 pathogen in humans; 

8 ‘‘(XII) enhance the immune eva9 sion of a pathogen in humans, such as 

10 by modifying the pathogen to disrupt 

11 the effectiveness of pre-existing immu12 nity via immunization or natural in13 fection; or 

14 ‘‘(XIII) generate, use, reconstitute, 

15 or transfer an eradicated or extinct 

16 high-consequence pathogen; and 

17 ‘‘(ii) any other category of life sciences 

18 research that the Board, by majority vote of 

19 the members of the Board, identifies and 

20 publishes in the Federal Register. 

21 ‘‘(5) EMPLOYEE.—The term ‘employee’ means an 

22 individual described in section 2105(a) of title 5. 

23 ‘‘(6) FEDERAL FUNDING.—The term ‘Federal 

24 funding’ means amounts awarded by an agency pur25 suant to an intramural or extramural grant, cooperaVerDate Sep 11 2014 00:24 Dec 06, 2024 Jkt 059200 PO 00000 Frm 00046 Fmt 6652 Sfmt 6203 E:\BILLS\S4667.RS S4667

ssavage on LAPJG3WLY3PROD with BILLS
47 

•S 4667 RS

1 tive agreement, interagency agreement, contract, or 

2 other instrument. 

3 ‘‘(7) GAIN OF FUNCTION RESEARCH.—The term 

4 ‘gain of function research’ means a research experi5 ment that may enhance the transmissibility or 

6 virulence of a high-consequence pathogen. 

7 ‘‘(8) HIGH-CONSEQUENCE PATHOGEN.—The term 

8 ‘high-consequence pathogen’— 

9 ‘‘(A) means a wild-type or synthetic patho10 gen that— 

11 ‘‘(i)(I) is likely capable of wide and 

12 uncontrollable spread in human popu13 lations; and 

14 ‘‘(II) would likely cause moderate to 

15 severe disease or mortality in humans; or 

16 ‘‘(ii) is— 

17 ‘‘(I) subject to subparagraph (B), 

18 influenza A virus; 

19 ‘‘(II) classified under subgenus 

20 Sarbecovirus; 

21 ‘‘(III) classified under subgenus 

22 Merbecovirus; 

23 ‘‘(IV) Variola orthopoxvirus; 

24 ‘‘(V) Mpox orthopoxvirus; 

25 ‘‘(VI) Nipah henipavirus; 


ssavage on LAPJG3WLY3PROD with BILLS
48 

•S 4667 RS

1 ‘‘(VII) Hendra henipavirus; 

2 ‘‘(VIII) Ebola orthoebolavirus; 

3 ‘‘(IX) Marburg marburgvirus 

4 ‘‘(X) Lassa mammarenavirus; 

5 ‘‘(XI) Junin arenavirus; 

6 ‘‘(XII) Crimean-Congo hemor7 rhagic fever orthonairovirus; 

8 ‘‘(XIII) Hantaan orthohantavirus; 

9 ‘‘(XIV) Sin Nombre 

10 orthohantavirus; 

11 ‘‘(XV) Yersinia pestis; 

12 ‘‘(XVI) a select agent or toxin, 

13 work with which poses a significant 

14 risk of deliberate misuse; 

15 ‘‘(XVII) any other pathogen or 

16 category of pathogen that a majority of 

17 members of the Board— 

18 ‘‘(aa) identifies as a high19 consequence pathogen; and 

20 ‘‘(bb) publishes in the Fed21 eral Register; or 

22 ‘‘(XVIII) any synthetic construct 

23 of a pathogen or category of pathogen 

24 described in this clause; and 


ssavage on LAPJG3WLY3PROD with BILLS
49 

•S 4667 RS

1 ‘‘(B) does not include a seasonal influenza 

2 virus, unless a seasonal influenza virus has been 

3 manipulated to include genetic sequences from a 

4 pathogen described in subparagraph (A). 

5 ‘‘(9) HIGH-RISK LIFE SCIENCES RESEARCH.— 

6 The term ‘high-risk life sciences research’ means life 

7 sciences research that is— 

8 ‘‘(A) dual use research of concern involving 

9 a high-consequence pathogen; or 

10 ‘‘(B) gain of function research. 

11 ‘‘(10) LIFE SCIENCES RESEARCH.—The term ‘life 

12 sciences research’— 

13 ‘‘(A) means the study or use of a living or14 ganism, a virus, or a product of a living orga15 nism or virus; and 

16 ‘‘(B) includes each discipline, methodology, 

17 and application of biology, including bio18 technology, genomics, proteomics, bioinformatics, 

19 and pharmaceutical and biomedical research and 

20 techniques. 

21 ‘‘(11) SELECT AGENT OR TOXIN.—The term ‘se22 lect agent or toxin’ means a select agent or toxin 

23 identified under— 


ssavage on LAPJG3WLY3PROD with BILLS
50 

•S 4667 RS

1 ‘‘(A) section 73.3(b) of title 42, Code of Fed2 eral Regulations, as in effect on the date of en3 actment of the Risky Research Review Act; 

4 ‘‘(B) section 331.3(b) of title 7, Code of Fed5 eral Regulations, as in effect on the date of en6 actment of the Risky Research Review Act; or 

7 ‘‘(C) section 121.3(b) of title 9, Code of Fed8 eral Regulations, as in effect on the date of en9 actment of the Risky Research Review Act. 

10 ‘‘§ 7902. Establishment and membership 

11 ‘‘(a) ESTABLISHMENT.—There is established as an 

12 independent agency within the Executive Branch a board 

13 to be known as the ‘Life Sciences Research Security Board’ 

14 to review proposed Federal funding for life sciences research 

15 in accordance with section 7906. 

16 ‘‘(b) APPOINTMENT OF MEMBERS.— 

17 ‘‘(1) IN GENERAL.—The President shall appoint, 

18 without regard to political affiliation, 9 individuals 

19 who are citizens of the United States to serve as mem20 bers of the Board for not more than 2 terms of 4 years 

21 each, including— 

22 ‘‘(A) the Executive Director appointed 

23 under section 7903(a); 

24 ‘‘(B) 5 nongovernmental scientists in a life 

25 sciences field; 


ssavage on LAPJG3WLY3PROD with BILLS
51 

•S 4667 RS

1 ‘‘(C) 2 nongovernmental national security 

2 experts; and 

3 ‘‘(D) 1 nongovernmental biosafety expert. 

4 ‘‘(2) PERIOD FOR NOMINATIONS.—The President 

5 shall make appointments, other than the Executive 

6 Director, to the Board not later than 30 days after 

7 the date of enactment of this chapter. 

8 ‘‘(3) CONSIDERATIONS OF RECOMMENDATIONS.— 

9 The President shall make appointments to the Board 

10 after considering individuals recommended by the 

11 chair and ranking member of the appropriate con12 gressional committees. 

13 ‘‘(4) QUALIFICATIONS.—Individuals appointed 

14 to the Board— 

15 ‘‘(A) shall— 

16 ‘‘(i) be impartial individuals; and 

17 ‘‘(ii) be distinguished individuals of 

18 high national professional reputation in 

19 their respective fields who are capable of ex20 ercising the independent and objective judg21 ment necessary to conduct an impartial as22 sessment of the potential risks and benefits 

23 associated with Federal funding of high-risk 

24 life sciences research to public health and 

25 national security; and 


ssavage on LAPJG3WLY3PROD with BILLS
52 

•S 4667 RS

1 ‘‘(B) may not be an employee on the date 

2 of the appointment or during the 3-year period 

3 preceding the date of the appointment. 

4 ‘‘(5) LIMITATIONS.—Not more than 4 concurrent 

5 members of the Board may be an employee, a subcon6 tractor, a previous employee, or a previous subcon7 tractor of— 

8 ‘‘(A) the Department of Defense; 

9 ‘‘(B) the Department of Homeland Security; 

10 ‘‘(C) the National Institute of Allergy and 

11 Infectious Diseases of the Department of Health 

12 and Human Services; 

13 ‘‘(D) the Office of the Director of National 

14 Intelligence; or 

15 ‘‘(E) the Department of Energy. 

16 ‘‘(6) CONSIDERATION BY THE SENATE.— 

17 ‘‘(A) IN GENERAL.—Nominations for ap18 pointment to the Executive Director of the Board 

19 shall be referred to the Committee on Homeland 

20 Security and Governmental Affairs of the Senate 

21 for consideration. 

22 ‘‘(B) RENOMINATION.—A member of the 

23 Board who is recommended to serve a second 

24 term shall be nominated for appointment to the 


ssavage on LAPJG3WLY3PROD with BILLS
53 

•S 4667 RS

1 Board, and such nomination shall be referred 

2 pursuant to subparagraph (A). 

3 ‘‘(7) VACANCY.—Not later than 30 days after the 

4 date on which a vacancy on the Board occurs, the va5 cancy shall be filled in the same manner as specified 

6 for the original appointment. 

7 ‘‘(8) REMOVAL.— 

8 ‘‘(A) IN GENERAL.—No member of the 

9 Board shall be removed from office, other than 

10 by— 

11 ‘‘(i) impeachment and conviction; 

12 ‘‘(ii) the action of the President for in13 efficiency, neglect of duty, malfeasance in 

14 office, physical disability, mental inca15 pacity, or any other condition that substan16 tially impairs the performance of the mem17 ber’s duties; or 

18 ‘‘(iii) the Board in accordance with 

19 subparagraph (B). 

20 ‘‘(B) ACTION BY BOARD.—If the Director of 

21 the Office of Government Ethics determines that 

22 participation by a member of the Board in high23 risk life sciences research constitutes a conflict of 

24 interest, the Board shall take steps to mitigate or 

25 manage the conflict, which may include removal. 


ssavage on LAPJG3WLY3PROD with BILLS
54 

•S 4667 RS

1 ‘‘(C) NOTICE OF REMOVAL BY PRESIDENT.— 

2 ‘‘(i) IN GENERAL.—In the case of the 

3 removal of a member of the Board by the 

4 President as described in subparagraph 

5 (A)(ii), not later than 10 days after the re6 moval, the President shall submit to the 

7 chair and ranking member of the appro8 priate congressional committees a report 

9 specifying the facts found and the grounds 

10 for removal. 

11 ‘‘(ii) PUBLICATION OF REPORT.—The 

12 President shall publish in the Federal Reg13 ister each report submitted under clause (i), 

14 except that the President may, if necessary 

15 to protect the rights of a person named in 

16 the report or to prevent undue interference 

17 with any pending prosecution, postpone or 

18 refrain from publicly publishing any or all 

19 of the report until the completion of such 

20 pending cases or pursuant to privacy pro21 tection requirements in law. 

22 ‘‘(c) MANDATORY CONFLICTS OF INTEREST REVIEW.— 

23 ‘‘(1) IN GENERAL.—The Board, in consultation 

24 with the Director of the Office of Government Ethics, 

25 shall— 


ssavage on LAPJG3WLY3PROD with BILLS
55 

•S 4667 RS

1 ‘‘(A) not later than 180 days after the date 

2 of the enactment of this chapter— 

3 ‘‘(i) establish criteria to determine 

4 whether there is a conflict of interest with 

5 respect to any individual appointed to the 

6 Board, taking into consideration require7 ments under Federal law relating to ethics 

8 requirements for employees; and 

9 ‘‘(ii) upon an appointment of a mem10 ber to the Board under subsection (a)(1) 

11 thereafter, conduct a review of each indi12 vidual nominated and appointed to the 

13 Board to ensure the individual does not 

14 have any conflict of interest under the cri15 teria established pursuant to clause (i); and 

16 ‘‘(B) periodically thereafter, conduct a re17 view of each individual nominated and ap18 pointed to the Board to ensure the individual 

19 does not have any conflict of interest under the 

20 criteria established pursuant to subparagraph 

21 (A)(i) during the term of service of the indi22 vidual. 

23 ‘‘(2) NOTIFICATION.— 

24 ‘‘(A) IN GENERAL.—Not later than 3 days 

25 after the date on which the Director of the Office 


ssavage on LAPJG3WLY3PROD with BILLS
56 

•S 4667 RS

1 of Government Ethics becomes aware that a 

2 member of the Board possesses a potential con3 flict of interest under the criteria established 

4 pursuant to paragraph (1)(A)(i), the Director of 

5 the Office of Government Ethics shall notify the 

6 chair and ranking member of the appropriate 

7 congressional committees of the potential conflict 

8 of interest. 

9 ‘‘(B) NOTIFICATION BY MEMBER.—Not later 

10 than 30 days after the date on which a member 

11 of the Board becomes aware that another member 

12 of the Board possesses a potential conflict of in13 terest under the criteria established pursuant to 

14 paragraph (1)(A)(i), the member of the Board or 

15 the Executive Director of the Board shall notify 

16 the chair and ranking member of the appro17 priate congressional committees of the potential 

18 conflict of interest. 

19 ‘‘(d) SECURITY CLEARANCES.—All members of the 

20 Board shall be granted all the necessary security clearances 

21 and accesses, including to relevant Presidential and depart22 ment or agency special access and compartmented access 

23 programs, in an accelerated manner, subject to the standard 

24 procedures for granting such clearances. All nominees for 

25 appointment to the Board shall qualify for the necessary 


ssavage on LAPJG3WLY3PROD with BILLS
57 

•S 4667 RS

1 security clearances and accesses prior to being considered 

2 for confirmation by the Committee on Homeland Security 

3 and Governmental Affairs of the Senate. 

4 ‘‘(e) PARTICIPATION IN HIGH-RISK LIFE SCIENCES

5 RESEARCH.— 

6 ‘‘(1) DISCLOSURE REQUIRED.—A member of the 

7 Board shall disclose whether the member has partici8 pated in or is currently participating in high-risk life 

9 sciences research. 

10 ‘‘(2) CONFLICTS OF INTEREST.— 

11 ‘‘(A) IN GENERAL.—The participation in 

12 high-risk life sciences research by a member of 

13 the Board— 

14 ‘‘(i) shall be considered a potential 

15 conflict of interest; and 

16 ‘‘(ii) shall be subject to scrutiny by the 

17 Director of the Office of Government Ethics. 

18 ‘‘(B) DETERMINATION.—If the Director of 

19 the Office of Government Ethics determines that 

20 participation by a member of the Board in high21 risk life sciences research constitutes a conflict of 

22 interest, the Board shall take steps to mitigate or 

23 manage the conflict, which may include— 


ssavage on LAPJG3WLY3PROD with BILLS
58 

•S 4667 RS

1 ‘‘(i) the recusal of the affected member 

2 from relevant discussions and determina3 tions; and 

4 ‘‘(ii) removal of the affected member 

5 from the Board. 

6 ‘‘(f) COMPENSATION OF MEMBERS.— 

7 ‘‘(1) IN GENERAL.—Subject to such rules as may 

8 be adopted by the Board, without regard to the provi9 sions of chapter 51 and subchapter III of chapter 53 

10 of title 5 relating to classification and General Sched11 ule pay rates, a member of the Board, other than the 

12 Executive Director, shall be compensated at a rate— 

13 ‘‘(A) proposed by the Executive Director 

14 and approved by the Board; 

15 ‘‘(B) not to exceed the rate of basic pay for 

16 level II of the Executive Schedule; and 

17 ‘‘(C) that is commensurate with— 

18 ‘‘(i) the time a member of the Board 

19 spends engaged in the performance of duties 

20 on the Board; and 

21 ‘‘(ii) necessary traveling expenses. 

22 ‘‘(2) OUTSIDE EMPLOYMENT.—Subject to terms 

23 and approval determined by the Director of the Office 

24 of Government Ethics, a member of the Board may 


ssavage on LAPJG3WLY3PROD with BILLS
59 

•S 4667 RS

1 maintain outside employment and affiliations while 

2 serving on the Board. 

3 ‘‘(g) OVERSIGHT.— 

4 ‘‘(1) SENATE.—The Committee on Homeland Se5 curity and Governmental Affairs of the Senate 

6 shall— 

7 ‘‘(A) have continuing legislative oversight 

8 jurisdiction in the Senate with respect to the of9 ficial conduct of the Board and agency compli10 ance with requirements issued by the Board; and 

11 ‘‘(B) have access to any records provided to 

12 or created by the Board. 

13 ‘‘(2) HOUSE OF REPRESENTATIVES.—The Com14 mittee on Oversight and Accountability of the House 

15 of Representatives shall— 

16 ‘‘(A) have continuing legislative oversight 

17 jurisdiction in the House of Representatives with 

18 respect to the official conduct of the Board and 

19 agency compliance with requirements issued by 

20 the Board; and 

21 ‘‘(B) have access to any records provided to 

22 or created by the Board. 

23 ‘‘(3) DUTY TO COOPERATE.—The Board shall 

24 have the duty to cooperate with the exercise of over25 sight jurisdiction described in this subsection. 


ssavage on LAPJG3WLY3PROD with BILLS
60 

•S 4667 RS

1 ‘‘(4) SECURITY CLEARANCES.—The chair and 

2 ranking member of the appropriate congressional 

3 committees, and designated committee staff, shall be 

4 granted all security clearances and accesses held by 

5 the Board, including to relevant Presidential and de6 partment or agency special access and compartmented 

7 access programs. 

8 ‘‘(h) OFFICE SPACE.— 

9 ‘‘(1) IN GENERAL.—In selecting office space for 

10 the Board, the Board shall exhaust options for unused 

11 office spaces owned by the Federal Government as of 

12 the date of enactment of this chapter. 

13 ‘‘(2) SECURE OFFICE SPACE.— 

14 ‘‘(A) REQUESTS.—In order to review or dis15 cuss classified information, the Board shall re16 quest an accommodation from relevant agencies 

17 to access sensitive compartmented information 

18 facilities on an as-needed basis. 

19 ‘‘(B) FULFILMENT.—The head of an agency 

20 from which the Board requests an accommoda21 tion under subparagraph (A) shall accommodate 

22 the request in a timely manner. 

23 ‘‘§ 7903. Board personnel 

24 ‘‘(a) EXECUTIVE DIRECTOR.— 


ssavage on LAPJG3WLY3PROD with BILLS
61 

•S 4667 RS

1 ‘‘(1) APPOINTMENT.—Not later than 45 days 

2 after the date of enactment of this chapter, the Presi3 dent shall appoint, by and with the advice and con4 sent of the Senate, 1 individual who is a citizen of 

5 the United States, without regard to political affili6 ation, to the position of Executive Director of the 

7 Board for a term of 4 years. 

8 ‘‘(2) QUALIFICATIONS.—The individual ap9 pointed as Executive Director under paragraph (1) 

10 shall be a private individual of integrity and impar11 tiality who— 

12 ‘‘(A) is a distinguished scientist in a life 

13 sciences field; and 

14 ‘‘(B) is not, and has not been for the 3-year 

15 period preceding the date of the appointment— 

16 ‘‘(i) an employee; or 

17 ‘‘(ii) a participant in high-risk life 

18 sciences research supported by Federal fund19 ing. 

20 ‘‘(3) SECURITY CLEARANCES.— 

21 ‘‘(A) IN GENERAL.—A candidate for Execu22 tive Director of the Board shall be granted all se23 curity clearances and accesses held by the Board, 

24 including to relevant Presidential and depart25 ment or agency special access and compartVerDate Sep 11 2014 00:24 Dec 06, 2024 Jkt 059200 PO 00000 Frm 00061 Fmt 6652 Sfmt 6203 E:\BILLS\S4667.RS S4667

ssavage on LAPJG3WLY3PROD with BILLS
62 

•S 4667 RS

1 mented access programs in an accelerated man2 ner, subject to the standard procedures for grant3 ing such clearances. 

4 ‘‘(B) QUALIFICATION PRIOR TO APPOINT5 MENT.—The President shall ensure that a can6 didate for Executive Director of the Board quali7 fies for the security clearances and accesses de8 scribed in subparagraph (A) prior to appoint9 ment. 

10 ‘‘(4) FUNCTIONS.—The Executive Director of the 

11 Board shall— 

12 ‘‘(A) serve as principal liaison to Congress 

13 and agencies; 

14 ‘‘(B) serve as chair of the Board; 

15 ‘‘(C) be responsible for the administration 

16 and coordination of the responsibilities of the 

17 Board; and 

18 ‘‘(D) be responsible for the administration 

19 of all official activities conducted by the Board. 

20 ‘‘(5) REMOVAL.—Notwithstanding section 

21 7902(b)(8), the Executive Director shall not be re22 moved for reasons other than for cause on the grounds 

23 of inefficiency, neglect of duty, malfeasance in office, 

24 physical disability, mental incapacity, or any other 

25 condition that substantially impairs the performance 


ssavage on LAPJG3WLY3PROD with BILLS
63 

•S 4667 RS

1 of the responsibilities of the Executive Director or the 

2 staff of the Board. 

3 ‘‘(6) TERMS.—An Executive Director of the 

4 Board shall not serve more than 2 terms. 

5 ‘‘(b) STAFF.— 

6 ‘‘(1) IN GENERAL.—Without regard to the provi7 sions of subchapter I of chapter 33 of title 5 governing 

8 appointments in the competitive service, the Board 

9 may appoint not more than 25 additional personnel 

10 to enable the Board and the Executive Director to 

11 perform the duties of the Board. 

12 ‘‘(2) QUALIFICATIONS.—Each individual ap13 pointed to the staff of the Board— 

14 ‘‘(A) shall be a citizen of the United States 

15 of integrity and impartiality; 

16 ‘‘(B) shall have expertise in the life sciences 

17 field or the national security field; and 

18 ‘‘(C) may not be a participant in any fed19 erally funded research activity on the date of the 

20 appointment or during the course of service of 

21 the individual on the Board. 

22 ‘‘(3) SECURITY CLEARANCES.— 

23 ‘‘(A) IN GENERAL.—A candidate for ap24 pointment to the staff of the Board shall be 

25 granted all security clearances and accesses held 


ssavage on LAPJG3WLY3PROD with BILLS
64 

•S 4667 RS

1 by the Board, including to relevant Presidential 

2 and department or agency special access and 

3 compartmented access programs, in an acceler4 ated manner, subject to the standard procedures 

5 for granting such clearances. 

6 ‘‘(B) CONDITIONAL EMPLOYMENT.— 

7 ‘‘(i) IN GENERAL.—The Board may 

8 offer conditional employment to a candidate 

9 for a staff position of the Board pending the 

10 completion of security clearance background 

11 investigations. During the pendency of such 

12 investigations, the Board shall ensure that 

13 any such employee does not have access to, 

14 or responsibility involving, classified or oth15 erwise restricted materials. 

16 ‘‘(ii) UNQUALIFIED STAFF.—If the 

17 Board determines that an individual hired 

18 on a conditional basis under clause (i) is 

19 not eligible or otherwise does not qualify for 

20 all security clearances necessary to carry 

21 out the responsibilities of the position for 

22 which conditional employment has been of23 fered, the Board shall immediately termi24 nate the individual’s employment. 

25 ‘‘(4) SUPPORT FROM AGENCIES.— 


ssavage on LAPJG3WLY3PROD with BILLS
65 

•S 4667 RS

1 ‘‘(A) IN GENERAL.—The head of each agen2 cy shall designate not less than 1 full-time em3 ployee of the agency as the representative of the 

4 agency to— 

5 ‘‘(i) provide technical assistance to the 

6 Board; and 

7 ‘‘(ii) support the review process of the 

8 Board with respect to the agency under sec9 tion 7906 in a non-voting staff capacity. 

10 ‘‘(B) PROHIBITION.—A representative of an 

11 agency designated under subparagraph (A) and 

12 any employee of an agency may not directly or 

13 indirectly influence in any capacity a deter14 mination by the Board under section 7906 with 

15 respect to life sciences research funded by the 

16 agency. 

17 ‘‘(c) COMPENSATION.—Subject to such rules as may be 

18 adopted by the Board, without regard to the provisions of 

19 title 5 governing appointments in the competitive service 

20 and without regard to the provisions of chapter 51 and sub21 chapter III of chapter 53 of that title relating to classifica22 tion and General Schedule pay rates, the Executive Director 

23 of the Board shall— 


ssavage on LAPJG3WLY3PROD with BILLS
66 

•S 4667 RS

1 ‘‘(1) be compensated at a rate not to exceed the 

2 rate of basic pay for level II of the Executive Sched3 ule; 

4 ‘‘(2) serve the entire tenure as Executive Director 

5 as 1 full-time employee; and 

6 ‘‘(3) appoint and fix the compensation of such 

7 other personnel as may be necessary to carry out this 

8 chapter. 

9 ‘‘§ 7904. Board mission and functions 

10 ‘‘(a) MISSION.—The mission of the Board shall be to 

11 issue an independent determination as to whether an agen12 cy may award Federal funding for proposed high-risk life 

13 sciences research, which shall be binding upon the agency. 

14 ‘‘(b) POWERS.—The Board shall have the authority to 

15 act in a manner to carry out the mission described in sub16 section (a), including authority to— 

17 ‘‘(1) prescribe regulations to carry out the re18 sponsibilities of the Board; 

19 ‘‘(2) establish a process for the review of Federal 

20 funding for high-risk life sciences research prior to the 

21 award of the Federal funding, which shall be binding 

22 upon an agency, including information designated as 

23 classified or otherwise protected from disclosure; 

24 ‘‘(3) direct an agency to make available to the 

25 Board additional information and records, including 


ssavage on LAPJG3WLY3PROD with BILLS
67 

•S 4667 RS

1 information designated as classified or otherwise pro2 tected from disclosure, that the Board determines are 

3 required to fulfill the functions and responsibilities 

4 Board under this chapter; 

5 ‘‘(4) review any classified research conducted or 

6 funded by any agency to determine whether the re7 search would be considered high-risk life sciences re8 search; and 

9 ‘‘(5) through the promulgation of regulations, es10 tablish processes, policies, and procedures of the 

11 Board for rendering decisions under this chapter. 

12 ‘‘(c) INITIAL REQUIREMENTS.—The Board shall— 

13 ‘‘(1) not later than 180 days after the date of ap14 pointment of the initial members of the Board under 

15 section 7902, publish procedures in the Federal Reg16 ister establishing the process for the review by the 

17 Board under section 7906; 

18 ‘‘(2) prior to the establishment of the procedures 

19 under paragraph (1), consult with the appropriate 

20 congressional committees and heads of agencies for 

21 purposes of developing such procedures; and 

22 ‘‘(3) not later than 270 days after the date of the 

23 enactment of this chapter, begin carrying out the du24 ties described in section 7906. 


ssavage on LAPJG3WLY3PROD with BILLS
68 

•S 4667 RS

1 ‘‘(d) RESPONSIVENESS TO CONGRESS.—Notwith2 standing any other provision of law, not later than 30 days 

3 after the date on which the Board receives a request for in4 formation from a Member of Congress, the Board shall re5 spond to the request. 

6 ‘‘(e) CONGRESSIONAL BRIEFINGS.—Not less frequently 

7 than quarterly, the Board shall brief the appropriate con8 gressional committees on the work of the Board. 

9 ‘‘(f) SELECT AGENT OR TOXIN UPDATES.— 

10 ‘‘(1) IN GENERAL.—Not later than 15 days after 

11 the date on which the Board receives a notification 

12 that a select agent or toxin has been added to a list 

13 of agent or toxins under a regulation described in 

14 paragraph (2), the Board shall— 

15 ‘‘(A) review the select agent or toxin; 

16 ‘‘(B) by majority vote of members of the 

17 Board, determine whether the select agent or 

18 toxin should be added into the definition of ‘se19 lect agent or toxin’ under section 7901; and 

20 ‘‘(C) publish any addition determined 

21 under subparagraph (B) in the Federal Register. 

22 ‘‘(2) REGULATIONS DESCRIBED.—A regulation 

23 described in this paragraph is— 

24 ‘‘(A) section 73.3(b) of title 42, Code of Fed25 eral Regulations, or any successor regulation; 


ssavage on LAPJG3WLY3PROD with BILLS
69 

•S 4667 RS

1 ‘‘(B) section 331.3(b) of title 7, Code of Fed2 eral Regulations, or any successor regulation; 

3 and 

4 ‘‘(C) section 121.3(b) of title 9, Code of Fed5 eral Regulations, or any successor regulation. 

6 ‘‘(g) FINAL DETERMINATION AUTHORITY.—In any 

7 dispute with an agency or entity relating to the classifica8 tion of life sciences research under this chapter, the Board 

9 shall retain final and ultimate authority in— 

10 ‘‘(1) determining whether the life sciences re11 search is high-risk life sciences research, dual use re12 search of concern involving a high-consequence patho13 gen or gain of function research; 

14 ‘‘(2) interpreting definitions in section 7901; 

15 and 

16 ‘‘(3) determining whether a proposed Federal 

17 award for life sciences research is subject to the review 

18 process of the Board under section 7906(a)(1). 

19 ‘‘§ 7905. Agency procedures; referral to Board 

20 ‘‘(a) IN GENERAL.— 

21 ‘‘(1) PROHIBITION.—The head of an agency may 

22 not award Federal funding for— 

23 ‘‘(A) high-risk life sciences research without 

24 approval by the Board under section 

25 7906(a)(1)(B); or 


ssavage on LAPJG3WLY3PROD with BILLS
70 

•S 4667 RS

1 ‘‘(B) life sciences research if the Board, in 

2 accordance with section 7906(a)(2)(A)(ii), sub3 mits notification to the agency under section 

4 7906(a)(2)(B)(i) that Board is reviewing the 

5 Federal funding for life sciences research under 

6 section 7906(a) until the date on which the 

7 Board makes a final determination with respect 

8 to the proposed Federal funding. 

9 ‘‘(2) EFFECTIVE DATE.—Paragraph (1) shall 

10 take effect on the date that is 180 days after the date 

11 of enactment of this chapter. 

12 ‘‘(b) HIGH-RISK ATTESTATION; SELECT AGENT OR

13 TOXIN DISCLOSURE; CERTIFICATION.— 

14 ‘‘(1) IN GENERAL.—An entity seeking Federal 

15 funding from an agency for life sciences research 

16 shall, under the penalty of perjury— 

17 ‘‘(A) attest whether— 

18 ‘‘(i) the life sciences research will con19 stitute high-risk life sciences research; and 

20 ‘‘(ii) the entity is performing active re21 search with a select agent or toxin; and 

22 ‘‘(B) if the entity is makes a positive attes23 tation under subparagraph (A), disclose the 

24 source of funding for all active research. 


ssavage on LAPJG3WLY3PROD with BILLS
71 

•S 4667 RS

1 ‘‘(2) ACTIVE RESEARCH WITH SELECT AGENTS

2 OR TOXINS.— 

3 ‘‘(A) IN GENERAL.—The head of an agency 

4 that receives a disclosure from an entity under 

5 paragraph (1)(B) shall submit to the Board the 

6 disclosure. 

7 ‘‘(B) BOARD INQUIRIES.—The Board may 

8 contact an entity that submits a disclosure under 

9 paragraph (1)(B) to request additional informa10 tion relating to the disclosure. 

11 ‘‘(3) AGENCY CERTIFICATION.— 

12 ‘‘(A) POSITIVE ATTESTATIONS.—The head of 

13 an agency making an award of Federal funding 

14 to an entity that makes a positive attestation 

15 under paragraph (1)(A)(i) shall— 

16 ‘‘(i) submit to the Board the high-risk 

17 life sciences proposal; and 

18 ‘‘(ii) using the process established by 

19 the head of the agency under paragraph (4), 

20 certify the validity of the attestation. 

21 ‘‘(B) NEGATIVE ATTESTATIONS.—The head 

22 of an agency making an award of Federal fund23 ing to an entity that makes a negative attesta24 tion under paragraph (1)(A)(i) shall— 

25 ‘‘(i) review the attestation; and 


ssavage on LAPJG3WLY3PROD with BILLS
72 

•S 4667 RS

1 ‘‘(ii) using the process established by 

2 the head of the agency under paragraph (4), 

3 certify the validity of the attestation. 

4 ‘‘(4) PROCESS FOR REVIEW.—The head of each 

5 agency that awards Federal funding for life sciences 

6 research, in consultation with the Board, shall estab7 lish and implement a process for identifying pro8 posals from entities seeking Federal funding for life 

9 sciences research from the agency that will constitute 

10 high-risk life sciences research. 

11 ‘‘(5) MAINTENANCE OF RECORDS.—The head of 

12 each agency shall— 

13 ‘‘(A) maintain records of the certification 

14 process described in paragraph (3) for each ap15 plication for Federal funding in accordance with 

16 chapter 31 of title 44; and 

17 ‘‘(B) make the records maintained under 

18 subparagraph (A) available for audit and review 

19 upon request by the Board. 

20 ‘‘(c) NOTIFICATION.— 

21 ‘‘(1) IN GENERAL.—Not later than 30 days be22 fore the date on which the head of an agency plans 

23 to award Federal funding to an entity for life sciences 

24 research, the head of the agency shall submit to the 

25 Board a notification of the proposed Federal funding. 


ssavage on LAPJG3WLY3PROD with BILLS
73 

•S 4667 RS

1 ‘‘(2) CONTENTS.—The notification of Federal 

2 funding for life sciences research required under para3 graph (1) shall include the attestation and certifi4 cation required under subsection (b). 

5 ‘‘(3) BOARD REQUESTS.— 

6 ‘‘(A) IN GENERAL.—The Board may request 

7 additional information from the head of an 

8 agency relating to a notification submitted under 

9 paragraph (1). 

10 ‘‘(B) PROVISION OF INFORMATION.—The 

11 head of an agency from which the Board request 

12 additional information under subparagraph (A) 

13 shall provide the information in a timely man14 ner. 

15 ‘‘(d) AGENCY PROCEDURES.—Not later than 180 days 

16 after the date on which the Board publishes the process of 

17 the Board in the Federal Register pursuant to section 

18 7904(c), the head of each agency shall publish on the website 

19 of the agency prepayment and preaward procedures of the 

20 agency with respect to Federal funding for life sciences re21 search to— 

22 ‘‘(1) guarantee that— 

23 ‘‘(A) all high-risk life science research pro24 posals are referred to the Board before the award 

25 of Federal funding by the agency; 


ssavage on LAPJG3WLY3PROD with BILLS
74 

•S 4667 RS

1 ‘‘(B) no Federal funding for high-risk life 

2 sciences research is awarded by the agency with3 out approval by the Board; and 

4 ‘‘(C) not later than 30 days before the date 

5 on which the head of the agency plans to award 

6 the Federal funding, the agency notifies the 

7 Board of the proposal for Federal funding; and 

8 ‘‘(2) otherwise ensure compliance with this chap9 ter. 

10 ‘‘(e) PROVISION OF ADDITIONAL INFORMATION.—Upon 

11 request by the Board, the head of an agency shall provide 

12 any information relating to Federal funding awards for life 

13 sciences research determined necessary by the Board to pro14 vide oversight of the agency. 

15 ‘‘(f) CHANGE IN CIRCUMSTANCES DURING RE16 SEARCH.—If, during the course of life sciences research in 

17 progress performed by an entity supported by Federal fund18 ing from an agency, circumstances arise such that the life 

19 sciences research in progress may constitute high-risk life 

20 sciences research in contravention to the attestation of the 

21 entity under subsection (b)(1)(A)(i)— 

22 ‘‘(1) the entity shall— 

23 ‘‘(A) not later than 24 hours after the iden24 tification of the change in circumstance, pause 

25 the life sciences research in progress; and 


ssavage on LAPJG3WLY3PROD with BILLS
75 

•S 4667 RS

1 ‘‘(B) not later than 5 days after the date of 

2 the identification of the change in circumstance, 

3 submit to the head of the agency a written notifi4 cation through an electronic or nonelectronic 

5 communication method that— 

6 ‘‘(i) notifies the head of the agency of 

7 the possibility that the life sciences research 

8 in progress may constitute high-risk life 

9 sciences research; and 

10 ‘‘(ii) includes a detailed description of 

11 each change in circumstance that may 

12 transform the life sciences research in 

13 progress into high-risk life sciences research; 

14 and 

15 ‘‘(2) the head of the agency shall— 

16 ‘‘(A) using the process of the agency estab17 lished under subsection (b)(4), determine whether 

18 the life sciences research in progress constitutes 

19 high-risk life sciences research; 

20 ‘‘(B) if the head of the agency makes a neg21 ative determination under subparagraph (A), in22 form the entity that the entity may resume the 

23 life sciences research in progress; and 

24 ‘‘(C) if the head of the agency makes a posi25 tive determination under subparagraph (A), imVerDate Sep 11 2014 00:24 Dec 06, 2024 Jkt 059200 PO 00000 Frm 00075 Fmt 6652 Sfmt 6203 E:\BILLS\S4667.RS S4667

ssavage on LAPJG3WLY3PROD with BILLS
76 

•S 4667 RS

1 mediately submit to the Board a notification of 

2 the Federal funding of high-risk life sciences re3 search in progress for review under section 

4 7906(a)(1). 

5 ‘‘(g) ENFORCEMENT.— 

6 ‘‘(1) APPLICANT REQUIREMENTS.—If an entity 

7 seeking or receiving Federal funding from an agency 

8 knowingly fails to make a true attestation under sub9 section (b)(1) or promptly notify the agency of a 

10 change in circumstance in accordance with subsection 

11 (f)(1), the head of the agency shall refer the entity to 

12 the appropriate entity for suspension and debarment 

13 proceedings relating to the receipt of Federal funding. 

14 ‘‘(2) REFERRAL TO INSPECTOR GENERAL.—The 

15 Board shall refer any employee of an agency respon16 sible for overseeing and reviewing research proposals 

17 relating to Federal funding that knowingly fails to 

18 comply with subsection (b)(3) to the inspector general 

19 of the agency. 

20 ‘‘(3) EMPLOYEE DISCIPLINE.— 

21 ‘‘(A) IN GENERAL.—The head of an agency 

22 employing an employee who knowingly violates 

23 any provision of subsection (b)(3) (or, in the case 

24 of the head of an agency who violates any proviVerDate Sep 11 2014 00:24 Dec 06, 2024 Jkt 059200 PO 00000 Frm 00076 Fmt 6652 Sfmt 6203 E:\BILLS\S4667.RS S4667

ssavage on LAPJG3WLY3PROD with BILLS
77 

•S 4667 RS

1 sion of subsection (b)(3), the President) shall im2 pose on that employee— 

3 ‘‘(i) disciplinary action in accordance 

4 with chapter 75 of title 5 or an equivalent 

5 procedure of the agency; and 

6 ‘‘(ii) permanent revocation of any ap7 plicable security clearance held by the em8 ployee. 

9 ‘‘(B) CONTRACTOR PENALTY.—In the case of 

10 contractor working under a contract with an 

11 agency who knowingly violates subsection (b)(1), 

12 the head of the agency shall refer the contractor 

13 to the appropriate entity for suspension and de14 barment proceedings relating to the receipt of 

15 Federal funding. 

16 ‘‘(C) EMPLOYEE DISCIPLINE REPORTS.— 

17 ‘‘(i) IN GENERAL.—Not later than 360 

18 days after the date of enactment of this Act, 

19 and not less frequently than once every 90 

20 days thereafter, the head of each agency 

21 shall submit to the Board and the appro22 priate congressional committees a report 

23 that discloses, for the period covered by the 

24 report, each violation by an employee of the 

25 agency of subsection (b)(3). 


ssavage on LAPJG3WLY3PROD with BILLS
78 

•S 4667 RS

1 ‘‘(ii) CONTENTS.—Each report sub2 mitted under clause (i) shall include, with 

3 respect to a violation described in that 

4 clause— 

5 ‘‘(I) the name and professional 

6 title of each employee engaged in the 

7 violation; 

8 ‘‘(II) a detailed explanation of the 

9 nature of the violation; and 

10 ‘‘(III) the date of the violation. 

11 ‘‘(iii) PUBLICATION.—Not later than 5 

12 days after the date on which the Board re13 ceives a report under clause (i), the Board 

14 shall publish on a publicly accessible and 

15 searchable website the amount of violations 

16 that have been committed under clause (i). 

17 ‘‘(h) SUBAWARD AND SUBCONTRACTOR DISCLO18 SURE.— 

19 ‘‘(1) IN GENERAL.—During the course of high20 risk life sciences research in progress performed by an 

21 entity supported by Federal funding from an agency, 

22 the entity shall— 

23 ‘‘(A) continuously disclose to the head of the 

24 agency any subcontracts or subawards made or 


ssavage on LAPJG3WLY3PROD with BILLS
79 

•S 4667 RS

1 planned to be made with the Federal funding; 

2 and 

3 ‘‘(B) obtain consent from the head of the 

4 agency before awarding a subcontract or award 

5 described in subparagraph (A). 

6 ‘‘(2) AGENCY SUBMISSION.—Not later than 30 

7 days after the date on which the head of an agency 

8 receives a disclosure under paragraph (1), the head of 

9 the agency shall submit to the Board the disclosure. 

10 ‘‘(3) BOARD INQUIRIES.— 

11 ‘‘(A) IN GENERAL.—The Board may contact 

12 an entity that submits a disclosure under para13 graph (1) to request additional information re14 lating to the disclosure. 

15 ‘‘(B) ACCESS TO REPORTS.—During the 

16 course of high-risk life sciences research in 

17 progress performed by an entity supported by 

18 Federal funding from an agency, upon request, 

19 the Board shall have access to every annual re20 port of— 

21 ‘‘(i) the agency; 

22 ‘‘(ii) the entity performing the high23 risk life sciences research; and 

24 ‘‘(iii) any subcontractor or subawardee 

25 of an entity described in clause (ii). 


ssavage on LAPJG3WLY3PROD with BILLS
80 

•S 4667 RS

1 ‘‘§ 7906. Board review 

2 ‘‘(a) IN GENERAL.— 

3 ‘‘(1) HIGH-RISK LIFE SCIENCES RESEARCH.— 

4 Not later than 120 days after the date on which the 

5 Board receives a notification from an agency under 

6 section 7905(c) relating to proposed Federal funding 

7 for life sciences research that constitutes high-risk life 

8 sciences research or the Board receives a notification 

9 from an agency under section 7905(f)(2)(C) relating 

10 to Federal funding of research in progress that con11 stitutes high-risk life sciences research, the Board 

12 shall— 

13 ‘‘(A) review the proposed Federal funding or 

14 high-risk life sciences research in progress; 

15 ‘‘(B) by a majority vote, determine whether 

16 the agency may award the proposed Federal 

17 funding or continue to award the Federal fund18 ing for the high-risk life sciences research in 

19 progress; and 

20 ‘‘(C) by a majority vote, determine with re21 spect to the high-risk life sciences research funded 

22 by the proposed Federal funding or Federal 

23 funding for high-risk life sciences research in 

24 progress— 


ssavage on LAPJG3WLY3PROD with BILLS
81 

•S 4667 RS

1 ‘‘(i) the minimum required biosafety 

2 containment level, engineering controls, and 

3 operational controls; 

4 ‘‘(ii) the minimum required biosecurity 

5 engineering controls and operational con6 trols; and 

7 ‘‘(iii) the minimum required personnel 

8 assurance controls. 

9 ‘‘(2) PROPOSED LIFE SCIENCES RESEARCH.— 

10 ‘‘(A) IN GENERAL.—With respect to pro11 posed Federal funding by an agency for life 

12 sciences research, the Board may— 

13 ‘‘(i) review the proposed Federal fund14 ing; and 

15 ‘‘(ii) determine whether the Board 

16 should review the proposed Federal funding 

17 in accordance with paragraph (1). 

18 ‘‘(B) NOTIFICATION.—If the Board makes a 

19 positive determination under subparagraph 

20 (A)(ii) with respect to proposed Federal funding 

21 by an agency— 

22 ‘‘(i) the Board shall notify the head of 

23 the agency; and 

24 ‘‘(ii) the head of the agency may not 

25 award the proposed Federal funding until 


ssavage on LAPJG3WLY3PROD with BILLS
82 

•S 4667 RS

1 the date on which the Board makes a final 

2 determination with respect to the proposed 

3 Federal funding under paragraph (1). 

4 ‘‘(3) PAST FUNDING.—With respect to life 

5 sciences research performed with Federal funding 

6 awarded by an agency before the date of enactment of 

7 this chapter, the Board may review and audit the re8 search in order to assess the compliance of the agency 

9 with the provisions of this chapter. 

10 ‘‘(4) ONGOING FUNDING FOR LIFE SCIENCES RE11 SEARCH.—With respect to Federal funding for life 

12 sciences research in progress awarded by an agency 

13 before the date of enactment of this Act that the Board 

14 determines may constitute high-risk life sciences re15 search, the Board may— 

16 ‘‘(A) direct the agency to temporarily sus17 pend the Federal funding; 

18 ‘‘(B) require the agency to provide complete 

19 information on the Federal funding in order for 

20 the Board to complete a review of the life 

21 sciences research under paragraph (1); and 

22 ‘‘(C) by a majority vote of members of the 

23 Board, determine whether the agency may con24 tinue the Federal funding. 

25 ‘‘(b) CONSIDERATIONS.— 


ssavage on LAPJG3WLY3PROD with BILLS
83 

•S 4667 RS

1 ‘‘(1) IN GENERAL.—In making a determination 

2 under subsection (a)(1)(B), the Board shall consider, 

3 with respect to the high-risk life sciences research that 

4 will be conducted with the proposed Federal funding 

5 or high-risk life sciences research in progress— 

6 ‘‘(A) whether the research poses a threat to 

7 public health; 

8 ‘‘(B) whether the research poses a threat to 

9 public safety; 

10 ‘‘(C) whether the research has a high prob11 ability of producing benefits for public health; 

12 ‘‘(D) whether the research poses a threat to 

13 large populations of animals and plants; 

14 ‘‘(E) whether the research poses a threat to 

15 national security; 

16 ‘‘(F) whether the research is proposed to be 

17 conducted at least in part in a foreign country; 

18 ‘‘(G) the reasonably anticipated material 

19 risks of the research; 

20 ‘‘(H) the reasonably anticipated informa21 tion risks of the research; 

22 ‘‘(I) the reasonably anticipated benefits of 

23 the research; 


ssavage on LAPJG3WLY3PROD with BILLS
84 

•S 4667 RS

1 ‘‘(J) whether the reasonably anticipated 

2 benefits of the research outweigh the reasonably 

3 anticipated risks; and 

4 ‘‘(K) whether the benefits of the research 

5 could be obtained through procedures posing 

6 lower risks. 

7 ‘‘(2) WEIGHT OF FACTORS.—The presence or ab8 sence of any factor under paragraph (1) shall not be 

9 decisive with respect to the determination of the 

10 Board under subsection (a)(1)(B). 

11 ‘‘(c) NOTICE FOLLOWING REVIEW AND DETERMINA12 TION.— 

13 ‘‘(1) AGENCY NOTIFICATION.—Not later than 5 

14 days after the date on which the Board makes a deter15 mination under subsection (a)(1)(B) with respect to 

16 Federal funding by an agency, the Executive Director 

17 of the Board shall notify the head of the agency of the 

18 determination. 

19 ‘‘(2) BOARD CONSULTATION.— 

20 ‘‘(A) IN GENERAL.—Not later than 10 days 

21 after receiving a notification from the Board 

22 under paragraph (1), the head of an agency may 

23 request a meeting with the Board to discuss the 

24 determination of the Board. 


ssavage on LAPJG3WLY3PROD with BILLS
85 

•S 4667 RS

1 ‘‘(B) BOARD RESPONSE.—The Board shall 

2 schedule a meeting requested by the head of an 

3 agency under subparagraph (A) in a timely 

4 manner. 

5 ‘‘(3) NOTIFICATION TO APPROPRIATE CONGRES6 SIONAL COMMITTEES.—If the Board determines that 

7 the head of an agency may not proceed with an 

8 award of proposed Federal funding under this section, 

9 the Executive Director of the Board shall notify the 

10 appropriate congressional committees when the Board 

11 notifies the head of the agency. 

12 ‘‘(d) REQUEST FOR EXPEDITED REVIEW.— 

13 ‘‘(1) DEFINITION.—In this subsection, the term 

14 ‘emergency research’ means high-risk life sciences re15 search submitted to the Board that relates to a public 

16 health emergency or addresses a specific national se17 curity concern. 

18 ‘‘(2) REQUEST; NOTIFICATION.—The head of an 

19 agency seeking expedited review from the Board to 

20 award Federal funding for emergency research 

21 shall— 

22 ‘‘(A) include a request for expedited review 

23 in the notification required under section 

24 7905(c); and 


ssavage on LAPJG3WLY3PROD with BILLS
86 

•S 4667 RS

1 ‘‘(B) on the date of the notification de2 scribed in subparagraph (A), submit to the 

3 Board and the appropriate congressional com4 mittees a notification that explains why the spe5 cific public health emergency or national secu6 rity concern necessitates expedited review under 

7 this subsection. 

8 ‘‘(3) INTERNAL PROCESS.—The Board shall es9 tablish an internal process under which the Board 

10 will give proposed emergency research expedited re11 view under this section. 

12 ‘‘(4) TEMPORARY EMERGENCY RESEARCH.—If 

13 the Board does not notify the head of an agency with 

14 a determination under subsection (a)(1)(B) with re15 spect to proposed emergency research by the 15 days 

16 after the date on which the head of the agency submits 

17 a request under paragraph (2)(A), the head of the 

18 agency may award Federal funding for the emergency 

19 research on a temporary basis. 

20 ‘‘(e) SCIENTIFIC EXPERT PANELS.— 

21 ‘‘(1) IN GENERAL.—The Board may establish a 

22 scientific panel of nongovernmental experts to advise 

23 the Board in the review by the Board of life sciences 

24 research pursuant to this chapter. 


ssavage on LAPJG3WLY3PROD with BILLS
87 

•S 4667 RS

1 ‘‘(2) POLICIES AND PROCEDURES.—The Board 

2 shall establish and publish in the Federal Register 

3 procedures and policies relating to conflicts of inter4 est, recusal, expertise, and related matters before the 

5 establishment of the panel described in paragraph (1). 

6 ‘‘(3) PROHIBITION.—An individual serving on 

7 the panel established under paragraph (1) may not 

8 advise the Board on any matter with respect to which 

9 the individuals has an identified or perceived conflict 

10 of interest. 

11 ‘‘(4) REPORT.— 

12 ‘‘(A) IN GENERAL.—Not later than 30 days 

13 after the date on which the Board establishes a 

14 panel established under paragraph (1), the 

15 Board shall submit to the appropriate congres16 sional committees a report that includes the 

17 names, qualifications, and any identified or per18 ceived conflicts of interest of individuals who 

19 serve on the panel. 

20 ‘‘(B) PANEL CHANGES.—Upon a change of 

21 personnel on the panel established under para22 graph (1), the Board shall immediately submit 

23 to the appropriate congressional committees an 

24 update to the report required under subpara25 graph (A). 


ssavage on LAPJG3WLY3PROD with BILLS
88 

•S 4667 RS

1 ‘‘(f) REPORT.— 

2 ‘‘(1) IN GENERAL.—Not later than 360 days 

3 after the date on which the Board establishes the 

4 panel described in subsection (e)(1), and annually 

5 thereafter, the Board shall submit to the appropriate 

6 congressional committees a report, which shall include 

7 a classified annex, summarizing, with respect to each 

8 determination by the Board under this section relat9 ing to high-risk life sciences research— 

10 ‘‘(A) the findings of the Board; 

11 ‘‘(B) the determination of the Board; 

12 ‘‘(C) the name and location of the entity 

13 proposing the life sciences research; 

14 ‘‘(D) the name and location of any recipi15 ent of a subaward or subcontractor of an entity 

16 proposing life sciences research and the nature of 

17 the participation of such a recipient or subcon18 tractor; and 

19 ‘‘(E) an account of significant challenges or 

20 problems, including procedural or substantive 

21 challenges or problems, that arise during the 

22 course of the work of the Board, including the 

23 views of any member of the Board who wishes to 

24 have those views included in the report. 


ssavage on LAPJG3WLY3PROD with BILLS
89 

•S 4667 RS

1 ‘‘(2) PUBLIC REPORT.—On the date on which the 

2 Board submits a report required under paragraph 

3 (1), the Board shall make the report, other than the 

4 classified annex included in the report, available on 

5 a website. 

6 ‘‘(g) EFFECTIVE DATE.—This section shall take effect 

7 on the date that is 270 days after the date of enactment 

8 of this chapter. 

9 ‘‘§ 7907. GAO Audits 

10 ‘‘The Comptroller General of the United States shall 

11 periodically audit the Board. 

12 ‘‘§ 7908. Funding 

13 ‘‘There is authorized to be appropriated to the Board 

14 to carry out this chapter $30,000,000 for each of fiscal years 

15 2025 through 2034.’’. 

16 (b) CLERICAL AMENDMENT.—The table of chapters for 

17 subtitle V of title 31, United States Code, is amended by 

18 adding at the end the following: 

‘‘79. Life Sciences Research Security Board ............................................... 7901’’. 

19 (c) FINANCIAL DISCLOSURE REPORTS OF BOARD

20 MEMBERS.—Section 13103(f) of title 5, United States Code, 

21 is amended— 

22 (1) in paragraph (11), by striking ‘‘and’’ at the 

23 end; 

24 (2) in paragraph (12), by striking the period at 

25 the end and inserting ‘‘; and’’; and 


ssavage on LAPJG3WLY3PROD with BILLS
90 

•S 4667 RS

1 (3) by adding at the end the following: 

2 ‘‘(13) a member of the Life Sciences Research Se3 curity Board established under section 7902 of title 

4 31.’’. 


ssavage on LAPJG3WLY3PROD with BILLS

ssavage on LAPJG3WLY3PROD with BILLS
Calendar No. 667 

118TH CONGRESS 

2D SESSION S. 4667 

[Report No. 118–264] 

A BILL 

To amend title 31, United States Code, to establish 

for other purposes. the Life Sciences Research Security Board, and 

DECEMBER 5, 2024 

Reported with an amendment 


ssavage on LAPJG3WLY3PROD with BILLS